PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



(51) International Patent Classification ⁶ :		(11) International Publication Number:	WO 99/28480
C12N 15/53, 15/55, 15/60, C12P 7/20, 7/18, C12N 1/15, 1/19, 1/21, 9/04, 9/16, 9/88	A1	(43) International Publication Date:	10 June 1999 (10.06.99)
(21) International Application Number: PCT/US9 (22) International Filing Date: 2 December 1998 (US, European patent (AT, BE,	CH, CY, DE, DK, ES, FI,
(30) Priority Data: 08/982,783 2 December 1997 (02.12.97)) t	Published With international search report	
(71) Applicants (for all designated States except US): PONT DE NEMOURS AND COMPANY [US/U Market Street, Wilmington, DE 19898 (US). GI INTERNATIONAL, INC. [US/US]; 4 Cambrid, 1870 Winton Road, Rochester, NY 14618 (US).	JS]; 10 ENECC	07 DR	
(72) Inventors; and (75) Inventors/Applicants (for US only): NAIR, Rar [IN/US]; 905-D Cloister Road, Wilmington, D (US). PAYNE, Mark, S. [US/US]; 2408 News Wilmington, DE 19808 (US). TRIMBUR, Do [US/US]; 349 Orchard Avenue, Redwood City, C (US). VALLE, Fernando [MX/US]; Apartment 2 Cadillac Way, Burlingame, CA 94010 (US).	DE 198 ell Dri onald, CA 946	09 ve, E. 01	
(74) Agent: FLOYD, Linda, A.; E.I. du Pont de Nem Company, Legal Patent Records Center, 1007 Mari Wilmington, DE 19898 (US).	nours a ket Stre	and eet,	
(54) Title: METHOD FOR THE PRODUCTION OF GL	YCER	OL BY RECOMBINANT ORGANISMS	
(57) Abstract			
Recombinant organisms are provided comprisin erol-3-phosphatase activity useful for the production of disruptions in the endogenous genes encoding proteins have	glyce	ol from a variety of carbon substrates. Th	e organisms further contain

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
ΑZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of Americ
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CII	Switzerland	KG	Kyrgyzstan	NO	Norway	zw	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

TITLE

METHOD FOR THE PRODUCTION OF GLYCEROL BY RECOMBINANT ORGANISMS FIELD OF INVENTION

5

10

15

20

25

30

35

The present invention relates to the field of molecular biology and the use of recombinant organisms for the production of glycerol and compounds derived from the glycerol biosynthetic pathway. More specifically the invention describes the construction of a recombinant cell for the production of glycerol and derived compounds from a carbon substrate, the cell containing foreign genes encoding proteins having glycerol-3-phosphate dehydrogenase (G3PDH) and glycerol-3-phosphatase (G3P phosphatase) activities where the endogenous genes encoding the glycerol-converting glycerol kinase and glycerol dehydrogenase activities have been deleted.

BACKGROUND

Glycerol is a compound in great demand by industry for use in cosmetics, liquid soaps, food, pharmaceuticals, lubricants, anti-freeze solutions, and in numerous other applications. The esters of glycerol are important in the fat and oil industry. Historically, glycerol has been isolated from animal fat and similar sources; however, the process is laborious and inefficient. Microbial production of glycerol is preferred.

Not all organisms have a natural capacity to synthesize glycerol. However, the biological production of glycerol is known for some species of bacteria, algae, and yeast. The bacteria Bacillus licheniformis and Lactobacillus lycopersica synthesize glycerol. Glycerol production is found in the halotolerant algae Dunaliella sp. and Asteromonas gracilis for protection against high external salt concentrations (Ben-Amotz et al., (1982) Experientia 38:49-52). Similarly, various osmotolerant yeast synthesize glycerol as a protective measure. Most strains of Saccharomyces produce some glycerol during alcoholic fermentation and this production can be increased by the application of osmotic stress (Albertyn et al., (1994) Mol. Cell. Biol. 14, 4135-4144). Earlier this century glycerol was produced commercially with Saccharomyces cultures to which steering reagents were added such as sulfites or alkalis. Through the formation of an inactive complex, the steering agents block or inhibit the conversion of acetaldehyde to ethanol; thus, excess reducing equivalents (NADH) are available to or "steered" towards dihydroxyacetone phosphate (DHAP) for reduction to produce glycerol. This method is limited by the partial inhibition of yeast growth that is due to the sulfites. This limitation can be partially overcome by the use of alkalis which create excess NADH equivalents by a different mechanism. In this practice, the alkalis initiated a Cannizarro

disproportionation to yield ethanol and acetic acid from two equivalents of acetaldehyde. Thus, although production of glycerol is possible from naturally occurring organisms, production is often subject to the need to control osmotic stress of the cultures and the production of sulfites. A method free from these limitations is desirable. Production of glycerol from recombinant organisms containing foreign genes encoding key steps in the glycerol biosynthetic pathway is one possible route to such a method.

5

10

15

20

25

30

35

A number of the genes involved in the glycerol biosynthetic pathway have been isolated. For example, the gene encoding glycerol-3-phosphate dehydrogenase (DAR1, GPD1) has been cloned and sequenced from Saccharomyces diastaticus (Wang et al., (1994), J. Bact. 176:7091-7095). The DAR1 gene was cloned into a shuttle vector and used to transform E. coli where expression produced active enzyme. Wang et al., supra, recognizes that DAR1 is regulated by the cellular osmotic environment but does not suggest how the gene might be used to enhance glycerol production in a recombinant organism.

Other glycerol-3-phosphate dehydrogenase enzymes have been isolated. For example, sn-glycerol-3-phosphate dehydrogenase has been cloned and sequenced from *S. cerevisiae* (Larason et al., (1993) *Mol. Microbiol.*, 10:1101). Albertyn et al., (1994) *Mol. Cell. Biol.*, 14:4135) teach the cloning of GPD1 encoding a glycerol-3-phosphate dehydrogenase from *S. cerevisiae*. Like Wang et al., both Albertyn et al. and Larason et al. recognize the osmo-sensitivity of the regulation of this gene but do not suggest how the gene might be used in the production of glycerol in a recombinant organism.

As with G3PDH, glycerol-3-phosphatase has been isolated from Saccharomyces cerevisiae and the protein identified as being encoded by the GPP1 and GPP2 genes (Norbeck et al., (1996) J. Biol. Chem., 271:13875). Like the genes encoding G3PDH, it appears that GPP2 is osmotically-induced.

Although the genes encoding G3PDH and G3P phosphatase have been isolated, there is no teaching in the art that demonstrates glycerol production from recombinant organisms with G3PDH/G3P phosphatase expressed together or separately. Further, there is no teaching to suggest that efficient glycerol production from any wild-type organism is possible using these two enzyme activities that does not require applying some stress (salt or an osmolyte) to the cell. In fact, the art suggests that G3PDH activities may not affect glycerol production. For example, Eustace ((1987), Can. J. Microbiol., 33:112-117)) teaches hybridized yeast strains that produced glycerol at greater levels than the parent strains. However, Eustace also demonstrates that G3PDH activity remained constant or slightly lower in the hybridized strains as opposed to the wild type.

Glycerol is an industrially useful material. However, other compounds may be derived from the glycerol biosynthetic pathway that also have commercial significance. For example, glycerol-producing organisms may be engineered to produce 1,3-propanediol (U.S. 5686276), a monomer having potential utility in the production of polyester fibers and the manufacture of polyurethanes and cyclic compounds. It is known for example that in some organisms, glycerol is converted to 3-hydroxypropionaldehyde and then to 1,3-propanediol through the actions of a dehydratase enzyme and an oxidoreductase enzyme, respectively. Bacterial strains able to produce 1,3-propanediol have been found, for example, in the groups Citrobacter. Clostridium, Enterobacter, Ilyobacter, Klebsiella, Lactobacillus, and Pelobacter. Glycerol dehydratase and diol dehydratase systems are described by Seyfried et al. (1996) J. Bacteriol. 178:5793-5796 and Tobimatsu et al. (1995) J. Biol. Chem. 270:7142-7148, respectively. Recombinant organisms, containing exogenous dehydratase enzyme, that are able to produce 1,3-propanediol have been described (U.S. 5686276). Although these organisms produce 1,3-propanediol, it is clear that they would benefit from a system that would minimize glycerol conversion.

5

10

15

There are a number of advantages in engineering a glycerol-producing 20 organism for the production of 1,3-propanediol where conversion of glycerol is minimized. A microorganism capable of efficiently producing glycerol under physiological conditions is industrially desirable, especially when the glycerol itself will be used as a substrate in vivo as part of a more complex catabolic or biosynthetic pathway that could be perturbed by osmotic stress or the addition of 25 steering agents (e.g., the production of 1,3-propanediol). Some attempts at creating glycerol kinase and glycerol dehydrogenase mutants have been made. For example, De Koning et al. (1990) Appl. Microbiol Biotechnol. 32:693-698 report the methanol-dependent production of dihydroxyacetone and glycerol by mutants of the methylotrophic yeast Hansenula polymorpha blocked in 30 dihydroxyacetone kinase and glycerol kinase. Methanol and an additional substrate, required to replenish the xyulose-5-phosphate co-substrate of the assimilation reaction, were used to produce glycerol; however, a dihydroxyacetone reductase (glycerol dehydrogenase) is also required. Similarly, Shaw and Cameron, Book of Abstracts, 211th ACS National Meeting, 35 New Orleans, LA, March 24-28 (1996), BIOT-154 Publisher: American Chemical Society, Washington, D. C., investigate the deletion of of ldhA (lactate dehydrogenase), glpK (glycerol kinase), and tpiA (triosephosphate isomerase) for the optimization of 1,3-propanedial production. They do not suggest the expression of cloned genes for G3PDH or G3P phosphatase for the

production of glycerol or 1,3-propanediol and they do not discuss the impact of glycerol dehydrogenase.

The problem to be solved, therefore, is the lack of a process to direct carbon flux towards glycerol production by the addition or enhancement of certain enzyme activities, especially G3PDH and G3P phosphatase which respectively catalyze the conversion of dihydroxyacetone phosphate (DHAP) to glycerol-3-phosphate (G3P) and then to glycerol. The problem is complicated by the need to control the carbon flux away from glycerol by deletion or decrease of certain enzyme activities, especially glycerol kinase and glycerol dehydrogenase which respectively catalyze the conversion of glycerol plus ATP to G3P and glycerol to dihydroxyacetone (or glyceraldehyde).

5

10

15

20

25

30

35

SUMMARY OF THE INVENTION

The present invention provides a method for the production of glycerol from a recombinant organism comprising: transforming a suitable host cell with an expression cassette comprising either one or both of (a) a gene encoding a protein having glycerol-3-phosphate dehydrogenase activity and (b) a gene encoding a protein having glycerol-3-phosphate phosphatase activity, where the suitable host cell contains a disruption in either one or both of (a) a gene encoding an endogenous glycerol kinase and (b) a gene encoding an endogenous glycerol dehydrogenase, wherein the disruption prevents the expression of active gene product; culturing the transformed host cell in the presence of at least one carbon source selected from the group consisting of monosaccharides, oligosaccharides, polysaccharides, and single-carbon substrates, whereby glycerol is produced; and recovering the glycerol produced.

The present invention further provides a process for the production of 1,3-propanediol from a recombinant organism comprising: transforming a suitable host cell with an expression cassette comprising either one or both of (a) a gene encoding a protein having glycerol-3-phosphate dehydrogenase activity and (b) a gene encoding a protein having glycerol-3-phosphate phosphatase activity, the suitable host cell having at least one gene encoding a protein having a dehydratase activity and having a disruption in either one or both of (a) a gene encoding an endogenous glycerol kinase and (b) a gene encoding an endogenous glycerol dehydrogenase, wherein the disruption in the genes of (a) or (b) prevents the expression of active gene product; culturing the transformed host cell in the presence of at least one carbon source selected from the group consisting of monosaccharides, oligosaccharides, polysaccharides, and single-carbon substrates whereby 1,3-propanediol is produced; and recovering the 1,3-propanediol produced.

Additionally, the invention provides for a process for the production of 1,3-propanediol from a recombinant organism where multiple copies of endogeneous genes are introduced.

Further embodiments of the invention include host cells transformed with heterologous genes for the glycerol pathway as well as host cells which contain endogeneous genes for the glycerol pathway.

5

10

15

20

25

Additionally, the invention provides recombinant cells suitable for the production either glycerol or 1,3-propanediol, the host cells having genes expressing either one or both of a glycerol-3-phosphate dehydrogenase activity and a glycerol-3-phosphate phosphatase activity wherein the cell also has disruptions in either one or both of a gene encoding an endogenous glycerol kinase and a gene encoding an endogenous glycerol dehydrogenase, wherein the disruption in the genes prevents the expression of active gene product.

BRIEF DÉSCRIPTION OF THE FIGURES, BIOLOGICAL DEPOSITS AND SEQUENCE LISTING

Figure 1 illustrates the representative enzymatic pathways involving glycerol metabolism.

Applicants have made the following biological deposits under the terms of the Budapest Treaty on the International Recognition of the Deposit of Micro-organisms for the Purposes of Patent Procedure:

Depositor Identification Reference	Int'l. Depository Designation	Date of Deposit
Escherichia coli pAH21/DH5α (containing the GPP2 gene)	ATCC 98187	26 September 1996
Escherichia coli (pDAR1A/AA200) (containing the DAR1 gene)	ATCC 98248	6 November 1996
FM5 Escherichia coli RJF10m (containing a glpK disruption)	ATCC 98597	25 November 1997
FM5 Escherichia coli MSP33.6 (containing a gldA disruption)	ATCC 98598	25 November 1997

"ATCC" refers to the American Type Culture Collection international depository located at 12301 Parklawn Drive, Rockville, MD 20852 U.S.A. The designation is the accession number of the deposited material.

Applicants have provided 43 sequences in conformity with the Rules for the Standard Representation of Nucleotide and Amino Acid Sequences in Patent Applications (Annexes I and II to the Decision of the President of the EPO, published in Supplement No. 2 to OJ EPO, 12/1992) and with 37 C.F.R.

30 1.821-1.825 and Appendices A and B (Requirements for Application Disclosures Containing Nucleotides and/or Amino Acid Sequences).

DETAILED DESCRIPTION OF THE INVENTION

The present invention solves the problem stated above by providing a method for the biological production of glycerol from a fermentable carbon source in a recombinant organism. The method provides a rapid, inexpensive and environmentally-responsible source of glycerol useful in the cosmetics and pharmaceutical industries. The method uses a microorganism containing cloned homologous or heterologous genes encoding glycerol-3-phosphate dehydrogenase (G3PDH) and/or glycerol-3-phosphatase (G3P phosphatase). These genes are expressed in a recombinant host having disruptions in genes encoding endogenous glycerol kinase and/or glycerol dehydrogenase enzymes. The method is useful for the production of glycerol, as well as any end products for which glycerol is an intermediate. The recombinant microorganism is contacted with a carbon source and cultured and then glycerol or any end products derived therefrom are isolated from the conditioned media. The genes may be incorporated into the host microorganism separately or together for the production of glycerol.

5

10

15

20

25

30

35

Applicants' process has not previously been described for a recombinant organism and required the isolation of genes encoding the two enzymes and their subsequent expression in a host cell having disruptions in the endogenous kinase and dehydrogenase genes. It will be appreciated by those familiar with this art that Applicants' process may be generally applied to the production compounds where glycerol is a key intermediate, e.g., 1,3-propanediol.

As used herein the following terms may be used for interpretation of the claims and specification.

The terms "glycerol-3-phosphate dehydrogenase" and "G3PDH" refer to a polypeptide responsible for an enzyme activity that catalyzes the conversion of dihydroxyacetone phosphate (DHAP) to glycerol-3-phosphate (G3P). *In vivo* G3PDH may be NADH; NADPH; or FAD-dependent. The NADH-dependent enzyme (EC 1.1.1.8) is encoded, for example, by several genes including GPD1 (GenBank Z74071x2), or GPD2 (GenBank Z35169x1), or GPD3 (GenBank G984182), or DAR1 (GenBank Z74071x2). The NADPH-dependent enzyme (EC 1.1.1.94) is encoded by *gpsA* (GenBank U321643, (cds 197911-196892) G466746 and L45246). The FAD-dependent enzyme (EC 1.1.99.5) is encoded by GUT2 (GenBank Z47047x23), or glpD (GenBank G147838), or glpABC (GenBank M20938).

The terms "glycerol-3-phosphatase", "sn-glycerol-3-phosphatase", or "d,l-glycerol phosphatase", and "G3P phosphatase" refer to a polypeptide responsible for an enzyme activity that catalyzes the conversion of glycerol-3-phosphate and water to glycerol and inorganic phosphate. G3P phosphatase is

encoded, for example, by GPP1 (GenBank Z47047x125), or GPP2 (GenBank U18813x11).

The term "glycerol kinase" refers to a polypeptide responsible for an enzyme activity that catalyzes the conversion of glycerol and ATP to glycerol-3-phosphate and ADP. The high energy phosphate donor ATP may be replaced by physiological substitutes (e.g. phosphoenolpyruvate). Glycerol kinase is encoded, for example, by GUT1 (GenBank U11583x19) and glpK (GenBank L19201).

5

30

35

The term "glycerol dehydrogenase" refers to a polypeptide responsible

for an enzyme activity that catalyzes the conversion of glycerol to
dihydroxyacetone (E.C. 1.1.1.6) or glycerol to glyceraldehyde (E.C. 1.1.1.72).

A polypeptide responsible for an enzyme activity that catalyzes the conversion of
glycerol to dihydroxyacetone is also referred to as a "dihydroxyacetone
reductas3". Glycerol dehydrogenase may be dependent upon NADH

(E.C. 1.1.1.6), NADPH (E.C. 1.1.1.72), or other cofactors (e.g.,
E.C. 1.1.99.22). A NADH-dependent glycerol dehydrogenase is encoded, for
example, by gldA (GenBank U00006).

The term "dehydratase enzyme" will refer to any enzyme that is capable of isomerizing or converting a glycerol molecule to the product

3-hydroxypropion-aldehyde. For the purposes of the present invention the dehydratase enzymes include a glycerol dehydratase (E.C. 4.2.1.30) and a diol dehydratase (E.C. 4.2.1.28) having preferred substrates of glycerol and 1,2-propanediol, respectively. In Citrobacter freundii, for example, glycerol dehydratase is encoded by three polypeptides whose gene sequences are represented by dhaB, dhaC and dhaE (GenBank U09771: base pairs 8556-10223, 10235-10819, and 10822-11250, respectively). In Klebsiella oxytoca, for example, diol dehydratase is encoded by three polypeptides whose gene sequences are represented by pddA, pddB, and pddC (GenBank D45071: base pairs 121-1785, 1796-2470, and 2485-3006, respectively).

The terms "GPD1", "DAR1", "OSG1", "D2830", and "YDL022W" will be used interchangeably and refer to a gene that encodes a cytosolic glycerol-3-phosphate dehydrogenase and is characterized by the base sequence given as SEQ ID NO:1.

The term "GPD2" refers to a gene that encodes a cytosolic glycerol-3-phosphate dehydrogenase and is characterized by the base sequence given in SEQ ID NO:2.

The terms "GUT2" and "YIL155C" are used interchangeably and refer to a gene that encodes a mitochondrial glycerol-3-phosphate dehydrogenase and is characterized by the base sequence given in SEO ID NO:3.

The terms "GPP1", "RHR2" and "YIL053W" are used interchangeably and refer to a gene that encodes a cytosolic glycerol-3-phosphatase and is characterized by the base sequence given in SEQ ID NO:4.

The terms "GPP2", "HOR2" and "YER062C" are used interchangeably and refer to a gene that encodes a cytosolic glycerol-3-phosphatase and is characterized by the base sequence given as SEQ ID NO:5.

5

10

15

20

25

30

35

The term "GUT1" refers to a gene that encodes a cytosolic glycerol kinase and is characterized by the base sequence given as SEQ ID NO:6. The term "glpK" refers to another gene that encodes a glycerol kinase and is characterized by the base sequence given in GeneBank L19201, base pairs 77347-78855.

The term "gldA" refers to a gene that encodes a glycerol dehydrogenase and is characterized by the base sequence given in GeneBank U00006, base pairs 3174-4316. The term "dhaD" refers to another gene that encodes a glycerol dehydrogenase and is characterized by the base sequence given in GeneBank U09771, base pairs 2557-3654.

As used herein, the terms "function" and "enzyme function" refer to the catalytic activity of an enzyme in altering the energy required to perform a specific chemical reaction. Such an activity may apply to a reaction in equilibrium where the production of both product and substrate may be accomplished under suitable conditions.

The terms "polypeptide" and "protein" are used interchangeably.

The terms "carbon substrate" and "carbon source" refer to a carbon source capable of being metabolized by host organisms of the present invention and particularly mean carbon sources selected from the group consisting of monosaccharides, oligosaccharides, polysaccharides, and one-carbon substrates or mixtures thereof.

"Conversion" refers to the metabolic processes of an organism or cell that by means of a chemical reaction degrades or alters the complexity of a chemical compound or substrate.

The terms "host cell" and "host organism" refer to a microorganism capable of receiving foreign or heterologous genes and additional copies of endogeneous genes and expressing those genes to produce an active gene product.

The terms "production cell" and "production organism" refer to a cell engineered for the production of glycerol or compounds that may be derived from the glycerol biosynthetic pathway. The production cell will be recombinant and contain either one or both of a gene that encodes a protein having a glycerol-3-phosphate dehydrogenase activity and a gene encoding a

protein having a glycerol-3-phosphatase activity. In addition to the G3PDH and G3P phosphatase genes, the host cell will contain disruptions in one or both of a gene encoding an endogenous glycerol kinase and a gene encoding an endogenous glycerol dehydrogenase. Where the production cell is designed to produce 1,3-propanediol, it will additionally contain a gene encoding a protein having a dehydratase activity.

5

10

15

20

25

30

35

The terms "foreign gene", "foreign DNA", "heterologous gene", and "heterologous DNA" all refer to genetic material native to one organism that has been placed within a different host organism.

The term "endogenous" as used herein with reference to genes or polypeptides expressed by genes, refers to genes or polypeptides that are native to a production cell and are not derived from another organism. Thus an "endogenous glycerol kinase" and an "endogenous glycerol dehydrogenase" are terms referring to polypeptides encoded by genes native to the production cell.

The terms "recombinant organism" and "transformed host" refer to any organism transformed with heterologous or foreign genes. The recombinant organisms of the present invention express foreign genes encoding G3PDH and G3P phosphatase for the production of glycerol from suitable carbon substrates. Additionally, the terms "recombinant organism" and "transformed host" refer to any organism transformed with endogenous (or homologous) genes so as to increase the copy number of the genes.

"Gene" refers to a nucleic acid fragment that expresses a specific protein, including regulatory sequences preceding (5' non-coding) and following (3' non-coding) the coding region. The terms "native" and "wild-type" gene refer to the gene as found in nature with its own regulatory sequences.

The terms "encoding" and "coding" refer to the process by which a gene, through the mechanisms of transcription and translation, produces an amino acid sequence. The process of encoding a specific amino acid sequence is meant to include DNA sequences that may involve base changes that do not cause a change in the encoded amino acid, or which involve base changes which may alter one or more amino acids, but do not affect the functional properties of the protein encoded by the DNA sequence. Therefore, the invention encompasses more than the specific exemplary sequences. Modifications to the sequence, such as deletions, insertions, or substitutions in the sequence which produce silent changes that do not substantially affect the functional properties of the resulting protein molecule are also contemplated. For example, alterations in the gene sequence which reflect the degeneracy of the genetic code, or which result in the production of a chemically equivalent amino acid at a given site, are contemplated; thus, a codon for the amino acid alanine, a

hydrophobic amino acid, may be substituted by a codon encoding another less hydrophobic residue, such as glycine, or a more hydrophobic residue, such as valine, leucine, or isoleucine. Similarly, changes which result in substitution of one negatively charged residue for another, such as aspartic acid for glutamic acid, or one positively charged residue for another, such as lysine for arginine. can also be expected to produce a biologically equivalent product. Nucleotide changes which result in alteration of the N-terminal and C-terminal portions of the protein molecule would also not be expected to alter the activity of the protein. In some cases, it may in fact be desirable to make mutants of the sequence in order to study the effect of alteration on the biological activity of the protein. Each of the proposed modifications is well within the routine skill in the art, as is determination of retention of biological activity in the encoded products. Moreover, the skilled artisan recognizes that sequences encompassed by this invention are also defined by their ability to hybridize, under stringent conditions (0.1X SSC, 0.1% SDS, 65 °C), with the sequences exemplified herein.

5

10

15

20

25

30

35

The term "expression" refers to the transcription and translation to gene product from a gene coding for the sequence of the gene product.

The terms "plasmid", "vector", and "cassette" as used herein refer to an extra chromosomal element often carrying genes which are not part of the central metabolism of the cell and usually in the form of circular double-stranded DNA molecules. Such elements may be autonomously replicating sequences, genome integrating sequences, phage or nucleotide sequences, linear or circular, of a single- or double-stranded DNA or RNA, derived from any source, in which a number of nucleotide sequences have been joined or recombined into a unique construction which is capable of introducing a promoter fragment and DNA sequence for a selected gene product along with appropriate 3' untranslated sequence into a cell. "Transformation cassette" refers to a specific vector containing a foreign gene and having elements in addition to the foreign gene that facilitate transformation of a particular host cell. "Expression cassette" refers to a specific vector containing a foreign gene and having elements in addition to the foreign gene that allow for enhanced expression of that gene in a foreign host.

The terms "transformation" and "transfection" refer to the acquisition of new genes in a cell after the incorporation of nucleic acid. The acquired genes may be integrated into chromosomal DNA or introduced as extrachromosomal replicating sequences. The term "transformant" refers to the cell resulting from a transformation.

The term "genetically altered" refers to the process of changing hereditary material by transformation or mutation. The terms "disruption" and "gene interrupt" as applied to genes refer to a method of genetically altering an organism by adding to or deleting from a gene a significant portion of that gene such that the protein encoded by that gene is either not expressed or not expressed in active form.

Glycerol Biosynthetic Pathway

5

10

15

20

25

30

35

It is contemplated that glycerol may be produced in recombinant organisms by the manipulation of the glycerol biosynthetic pathway found in most microorganisms. Typically, a carbon substrate such as glucose is converted to glucose-6-phosphate via hexokinase in the presence of ATP. Glucose-phosphate isomerase catalyzes the conversion of glucose-6-phosphate to fructose-6-phosphate and then to fructose-1,6-diphosphate through the action of 6-phosphofructokinase. The diphosphate is then taken to dihydroxyacetone phosphate (DHAP) via aldolase. Finally NADH-dependent G3PDH converts DHAP to glycerol-3-phosphate which is then dephosphorylated to glycerol by G3P phosphatase. (Agarwal (1990), *Adv. Biochem. Engrg.* 41:114). Genes encoding G3PDH, glycerol dehydrogenase, G3P phosphatase and glycerol kinase

The present invention provides genes suitable for the expression of G3PDH and G3P phosphatase activities in a host cell.

Genes encoding G3PDH are known. For example, GPD1 has been isolated from *Saccharomyces* and has the base sequence given by SEQ ID NO:1, encoding the amino acid sequence given in SEQ ID NO:7 (Wang et al., *supra*). Similarly, G3PDH activity has also been isolated from *Saccharomyces* encoded by GPD2 having the base sequence given in SEQ ID NO:2 encoding the amino acid sequence given in SEQ ID NO:8 (Eriksson et al., (1995) *Mol. Microbiol.*, 17:95).

For the purposes of the present invention it is contemplated that any gene encoding a polypeptide responsible for G3PDH activity is suitable wherein that activity is capable of catalyzing the conversion of dihydroxyacetone phosphate (DHAP) to glycerol-3-phosphate (G3P). Further, it is contemplated that any gene encoding the amino acid sequence of G3PDH as given by SEQ ID NOS:7, 8, 9, 10, 11 and 12 corresponding to the genes GPD1, GPD2, GUT2, gpsA, glpD, and the α subunit of glpABC respectively, will be functional in the present invention wherein that amino acid sequence may encompass amino acid substitutions, deletions or additions that do not alter the function of the enzyme. The skilled person will appreciate that genes encoding G3PDH isolated from other sources will also be suitable for use in the present invention. For

example, genes isolated from prokaryotes include GenBank accessions M34393, M20938, L06231, U12567, L45246, L45323, L45324, L45325, U32164, U32689, and U39682. Genes isolated from fungi include GenBank accessions U30625, U30876 and X56162; genes isolated from insects include GenBank accessions X61223 and X14179; and genes isolated from mammalian sources include GenBank accessions U12424, M25558 and X78593.

5

10

15

20

25

30

35

Genes encoding G3P phosphatase are known. For example, GPP2 has been isolated from *Saccharomyces cerevisiae* and has the base sequence given by SEQ ID NO:5, which encodes the amino acid sequence given in SEQ ID NO:13 (Norbeck et al., (1996), *J. Biol. Chem.*, 271:13875).

For the purposes of the present invention, any gene encoding a G3P phosphatase activity is suitable for use in the method wherein that activity is capable of catalyzing the conversion of glycerol-3-phosphateand water to glycerol and inorganic phosphate. Further, any gene encoding the amino acid sequence of G3P phosphatase as given by SEQ ID NOS:13 and 14 corresponding to the genes GPP2 and GPP1 respectively, will be functional in the present invention including any amino acid sequence that encompasses amino acid substitutions, deletions or additions that do not alter the function of the G3P phosphatase enzyme. The skilled person will appreciate that genes encoding G3P phosphatase isolated from other sources will also be suitable for use in the present invention. For example, the dephosphorylation of glycerol-3-phosphate to yield glycerol may be achieved with one or more of the following general or specific phosphatases: alkaline phosphatase (EC 3.1.3.1) [GenBank M19159, M29663, U02550 or M33965]; acid phosphatase (EC 3.1.3.2) [GenBank U51210, U19789, U28658 or L20566]; glycerol-3-phosphatase (EC 3.1.3.-) [GenBank Z38060 or U18813x11]; glucose-1-phosphatase (EC 3.1.3.10) [GenBank M33807]; glucose-6-phosphatase (EC 3.1.3.9) [GenBank U00445]: fructose-1,6-bisphosphatase (EC 3.1.3.11) [GenBank X12545 or J03207] or phosphotidyl glycero phosphate phosphatase (EC 3.1.3.27) [GenBank M23546 and M23628].

Genes encoding glycerol kinase are known. For example, GUT1 encoding the glycerol kinase from *Saccharomyces* has been isolated and sequenced (Pavlik et al. (1993), *Curr. Genet.*, 24:21) and the base sequence is given by SEQ ID NO:6, which encodes the amino acid sequence given in SEQ ID NO:15. Alternatively, *glpK* encodes a glycerol kinase from *E. coli* and is characterized by the base sequence given in GeneBank L19201, base pairs 77347-78855.

Genes encoding glycerol dehydrogenase are known. For example, gldA encodes a glycerol dehydrogenase from E. coli and is characterized by the base

sequence given in GeneBank U00006, base pairs 3174-4316. Alternatively, dhaD refers to another gene that encodes a glycerol dehydrogenase from Citrobacter freundii and is characterized by the base sequence given in GeneBank U09771, base pairs 2557-3654.

5 Host cells

10

15

20

25

30

35

Suitable host cells for the recombinant production of glycerol by the expression of G3PDH and G3P phosphatase may be either prokaryotic or eukaryotic and will be limited only by their ability to express active enzymes. Preferred host cells will be those bacteria, yeasts, and filamentous fungi typically useful for the production of glycerol such as Citrobacter, Enterobacter, Clostridium, Klebsiella, Aerobacter, Lactobacillus, Aspergillus, Saccharomyces, Schizosaccharomyces, Zygosaccharomyces, Pichia, Kluyveromyces, Candida, Hansenula, Debaryomyces, Mucor, Torulopsis, Methylobacter, Escherichia, Salmonella, Bacillus, Streptomyces and Pseudomonas. Preferred in the present invention are E. coli and Saccharomyces.

Where glycerol is a key intermediate in the production of 1,3-propane-diol the host cell will either have an endogenous gene encoding a protein having a dehydratase activity or will acquire such a gene through transformation. Host cells particularly suited for production of 1,3-propanediol are Citrobacter, Enterobacter, Clostridium, Klebsiella, Aerobacter, Lactobacillus, and Salmonella, which have endogenous genes encoding dehydratase enzymes. Additionally, host cells that lack such an endogeneous gene include E. coli. Vectors And Expression Cassettes

The present invention provides a variety of vectors and transformation and expression cassettes suitable for the cloning, transformation and expression of G3PDH and G3P phosphatase into a suitable host cell. Suitable vectors will be those which are compatible with the bacterium employed. Suitable vectors can be derived, for example, from a bacteria, a virus (such as bacteriophage T7 or a M-13 derived phage), a cosmid, a yeast or a plant. Protocols for obtaining and using such vectors are known to those in the art (Sambrook et al., Molecular Cloning: A Laboratory Manual - volumes 1, 2, 3 (Cold Spring Harbor Laboratory: Cold Spring Harbor, NY, 1989)).

Typically, the vector or cassette contains sequences directing transcription and translation of the appropriate gene, a selectable marker, and sequences allowing autonomous replication or chromosomal integration. Suitable vectors comprise a region 5' of the gene which harbors transcriptional initiation controls and a region 3' of the DNA fragment which controls transcriptional termination. It is most preferred when both control regions are derived from genes homologous to the transformed host cell. Such control

regions need not be derived from the genes native to the specific species chosen as a production host.

Initiation control regions, or promoters, which are useful to drive expression of the G3PDH and G3P phosphatase genes in the desired host cell are numerous and familiar to those skilled in the art. Virtually any promoter capable of driving these genes is suitable for the present invention including but not limited to CYC1, HIS3, GAL1, GAL10, ADH1, PGK, PHO5, GAPDH, ADC1, TRP1, URA3, LEU2, ENO, and TPI (useful for expression in Saccharomyces); AOX1 (useful for expression in Pichia); and lac, trp, λP_L, λP_R, T7, tac, and trc, (useful for expression in E. coli).

5

10

15

20

25

30

35

Termination control regions may also be derived from various genes native to the preferred hosts. Optionally, a termination site may be unnecessary; however, it is most preferred if included.

For effective expression of the instant enzymes, DNA encoding the enzymes are linked operably through initiation codons to selected expression control regions such that expression results in the formation of the appropriate messenger RNA.

Transformation Of Suitable Hosts And Expression Of G3PDH And G3P Phosphatase For The Production Of Glycerol

Once suitable cassettes are constructed they are used to transform appropriate host cells. Introduction of the cassette containing the genes encoding G3PDH and/or G3P phosphatase into the host cell may be accomplished by known procedures such as by transformation, e.g., using calcium-permeabilized cells, electroporation, or by transfection using a recombinant phage virus (Sambrook et al., *supra*).

In the present invention AH21 and DAR1 cassettes were used to transform the $E.\ coli\ DH5\alpha$ and FM5 as fully described in the GENERAL METHODS and EXAMPLES.

Alternatively, it is contemplated that suitable host cells comprising endogenous G3PDH and/or G3P phosphatase genes may be manipulated so that the relevant genes are upregulated for the production of glycerol.

Methods for upregulation of endogenous genes are well known in the art. For example, to upregulate the desired gene(s), a structural gene is generally placed downstream from a promoter region on the DNA which is recognized by the recipient microorganism. In addition to the promoter, one may include other regulatory sequences that increase or control expression from heterologous genes. In addition, one may alter the regulatory sequences of endogenous genes by any known genetic manipulation for the same purpose. Expression may be controlled

by an inducer or a repressor so that the microorganism coordinately expresses the gene(s) necessary to complete the desired metabolic pathway.

5

10

15

20

25

30

35

In the instant invention host cells containing endogenous genes encoding G3PDH and/or G3P phosphatase activities could be placed under the control of regulated promoters (e.g. *lac* or *osmy*) or constitutive promoters. For example, a cassette may be constructed to contain a specific inducible or constitutive promoter, flanked by DNA of sufficient length and homology to the native gene to permit targeting. Introduction of the cassette under suitable growth conditions will result in homologous recombination between the cassette and the targeted portion of the gene and the replacement of the relevant native promoter with the regulatable promoter. Such methods may be employed to effect the upregulation of endogenous genes encoding G3PDH and/or G3P phosphatase activities for the production of glycerol.

Random And Site Specific Mutagenisis For Disrupting Enzyme Activities:

Enzyme pathways by which organisms metabolize glycerol are known in the art, Figure 1. Glycerol is converted to glycerol-3-phosphate (G3P) by an ATP-dependent glycerol kinase; the G3P may then be oxidized to DHAP by G3PDH. In a second pathway, glycerol is oxidized to dihydroxyacetone (DHA) by a glycerol dehydrogenase; the DHA may then be converted to DHAP by an ATP-dependent DHA kinase. In a third pathway, glycerol is oxidized to glyceraldehyde by a glycerol dehydrogenase; the glyceraldehyde may be phosphorylated to glyceraldehyde-3-phosphate by an ATP-dependent kinase. DHAP and glyceraldehyde-3-phosphate, interconverted by the action of triosephosphate isomerase, may be further metabolized via central metabolism pathways. These pathways, by introducing by-products, are deleterious to glycerol production.

One aspect of the present invention is the ability to provide a production organism for the production of glycerol where the glycerol-converting activities of glycerol kinase and glycerol dehydrogenase have been deleted. Methods of creating deletion mutants are common and well known in the art. For example, wild type cells may be exposed to a variety of agents such as radiation or chemical mutagens and then screened for the desired phenotype. When creating mutations through radiation either ultraviolet (UV) or ionizing radiation may be used. Suitable short wave UV wavelengths for genetic mutations will fall within the range of 200 nm to 300 nm where 254 nm is preferred. UV radiation in this wavelength principally causes changes within nucleic acid sequence from guanidine and cytosine to adenine and thymidine. Since all cells have DNA repair mechanisms that would repair most UV induced mutations, agents such as caffeine and other inhibitors may be added to interrupt the repair process and

maximize the number of effective mutations. Long wave UV mutations using light in the 300 nm to 400 nm range are also possible but are generally not as effective as the short wave UV light unless used in conjunction with various activators such as psoralen dyes that interact with the DNA.

Mutagenesis with chemical agents is also effective for generating mutants and commonly used substances include chemicals that affect nonreplicating DNA such as HNO₂ and NH₂OH, as well as agents that affect replicating DNA such as acridine dyes, notable for causing frameshift mutations. Specific methods for creating mutants using radiation or chemical agents are well documented in the art. See for example Thomas D. Brock in Biotechnology: A Textbook of Industrial Microbiology, Second Edition (1989) Sinauer Associates, Inc., Sunderland, MA., or Deshpande, Mukund V., Appl. Biochem. Biotechnol., 36, 227, (1992), herein incorporated by reference.

After mutagenesis has occurred, mutants having the desired phenotype may be selected by a variety of methods. Random screening is most common where the mutagenized cells are selected for the ability to produce the desired product or intermediate. Alternatively, selective isolation of mutants can be performed by growing a mutagenized population on selective media where only resistant colonies can develop. Methods of mutant selection are highly developed and well known in the art of industrial microbiology. See Brock, Supra., DeMancilha et al., Food Chem., 14, 313, (1984).

Biological mutagenic agents which target genes randomly are well known in the art. See for example De Bruijn and Rossbach in Methods for General and Molecular Bacteriology (1994) American Society for Microbiology,

Washington, D.C. Alternatively, provided that gene sequence is known, chromosomal gene disruption with specific deletion or replacement is achieved by homologous recombination with an appropriate plasmid. See for example Hamilton et al. (1989) J. Bacteriol. 171:4617-4622, Balbas et al. (1993) Gene 136:211-213, Gueldener et al. (1996) Nucleic Acids Res. 24:2519-2524, and
Smith et al. (1996) Methods Mol. Cell. Biol. 5:270-277.

It is contemplated that any of the above cited methods may be used for the deletion or inactivation of glycerol kinase and glycerol dehydrogenase activities in the preferred production organism.

Media and Carbon Substrates

5

10

15

20

35

Fermentation media in the present invention must contain suitable carbon substrates. Suitable substrates may include but are not limited to monosaccharides such as glucose and fructose, oligosaccharides such as lactose or sucrose, polysaccharides such as starch or cellulose or mixtures thereof and unpurified mixtures from renewable feedstocks such as cheese whey permeate,

cornsteep liquor, sugar beet molasses, and barley malt. Additionally, the carbon substrate may also be one-carbon substrates such as carbon dioxide, or methanol for which metabolic conversion into key biochemical intermediates has been demonstrated.

5

10

15

20

25

30

35

Glycerol production from single carbon sources (e.g., methanol, formaldehyde or formate) has been reported in methylotrophic yeasts (Yamada et al. (1989), Agric. Biol. Chem., 53(2):541-543) and in bacteria (Hunter et al. (1985), Biochemistry, 24:4148-4155). These organisms can assimilate single carbon compounds, ranging in oxidation state from methane to formate, and produce glycerol. The pathway of carbon assimilation can be through ribulose monophosphate, through serine, or through xylulose-monophosphate (Gottschalk, Bacterial Metabolism, Second Edition, Springer-Verlag: New York (1986)). The ribulose monophosphate pathway involves the condensation of formate with ribulose-5-phosphate to form a 6 carbon sugar that becomes fructose and eventually the three carbon product, glyceraldehyde-3-phosphate. Likewise, the serine pathway assimilates the one-carbon compound into the glycolytic pathway via methylenetetrahydrofolate.

In addition to one and two carbon substrates, methylotrophic organisms are also known to utilize a number of other carbon-containing compounds such as methylamine, glucosamine and a variety of amino acids for metabolic activity. For example, methylotrophic yeast are known to utilize the carbon from methylamine to form trehalose or glycerol (Bellion et al. (1993), *Microb*. *Growth C1 Compd*., [Int. Symp.], 7th, 415-32. Editor(s): Murrell, J. Collin; Kelly, Don P. Publisher: Intercept, Andover, UK). Similarly, various species of *Candida* will metabolize alanine or oleic acid (Sulter et al. (1990), *Arch*. *Microbiol.*, 153(5):485-9). Hence, the source of carbon utilized in the present invention may encompass a wide variety of carbon-containing substrates and will only be limited by the choice of organism.

Although all of the above mentioned carbon substrates and mixtures thereof are suitable in the present invention, preferred carbon substrates are monosaccharides, oligosaccharides, polysaccharides, single-carbon substrates or mixtures thereof. More preferred are sugars such as glucose, fructose, sucrose, maltose, lactose and single carbon substrates such as methanol and carbon dioxide. Most preferred as a carbon substrate is glucose.

In addition to an appropriate carbon source, fermentation media must contain suitable minerals, salts, cofactors, buffers and other components, known to those skilled in the art, suitable for the growth of the cultures and promotion of the enzymatic pathway necessary for glycerol production.

Culture Conditions

15

20

25

30

35

Typically cells are grown at 30 °C in appropriate media. Preferred growth media are common commercially prepared media such as Luria Bertani (LB) broth, Sabouraud Dextrose (SD) broth, or Yeast medium (YM) broth.

5 Other defined or synthetic growth media may also be used and the appropriate medium for growth of the particular microorganism will be known by one skilled in the art of microbiology or fermentation science. The use of agents known to modulate catabolite repression directly or indirectly, e.g., cyclic adenosine 3':5'-monophosphate, may also be incorporated into the reaction media. Similarly, the use of agents known to modulate enzymatic activities (e.g., sulfites, bisulfites, and alkalis) that lead to enhancement of glycerol production may be used in conjunction with or as an alternative to genetic manipulations.

Suitable pH ranges for the fermentation are between pH 5.0 to pH 9.0 where the range of pH 6.0 to pH 8.0 is preferred for the initial condition.

Reactions may be performed under aerobic or anaerobic conditions where anaerobic or microaerobic conditions are preferred.

Identification of G3PDH, glycerol dehydrogenase, G3P phosphatase, and glycerol kinase activities

The levels of expression of the proteins G3PDH, G3P phosphatase glycerol dehydrogenase, and glycerol kinase are measured by enzyme assays. Generally, G3PDH activity and glycerol dehydrogenase activity assays rely on the spectral properties of the cosubstrate, NADH, in the DHAP conversion to G-3-P and the DHA conversion to glycerol, respectively. NADH has intrinsic UV/vis absorption and its consumption can be monitored spectrophotometrically at 340 nm. G3P phosphatase activity can be measured by any method of measuring the inorganic phosphate liberated in the reaction. The most commonly used detection method uses the visible spectroscopic determination of a blue-colored phosphomolybdate ammonium complex. Glycerol kinase activity can be measured by the detection of G3P from glycerol and ATP, for example, by NMR. Assays can be directed toward more specific characteristics of individual enzymes if necessary, for example, by the use of alternate cofactors. Identification and recovery of glycerol and other products (e.g. 1,3-propanediol)

Glycerol and other products (e.g. 1,3-propanediol) may be identified and quantified by high performance liquid chromatography (HPLC) and gas chromatography/mass spectroscopy (GC/MS) analyses on the cell-free extracts. Preferred is a HPLC method where the fermentation media are analyzed on an analytical ion exchange column using a mobile phase of 0.01N sulfuric acid in an isocratic fashion.

Methods for the recovery of glycerol from fermentation media are known in the art. For example, glycerol can be obtained from cell media by subjecting the reaction mixture to the following sequence of steps: filtration; water removal; organic solvent extraction; and fractional distillation (U.S. Patent No. 2,986,495).

Description Of The Preferred Embodiments

Production of Glycerol

5

10

15

20

25

30

35

The present invention describes a method for the production of glycerol from a suitable carbon source utilizing a recombinant organism. Particularly suitable in the invention is a bacterial host cell, transformed with an expression cassette carrying either or both of a gene that encodes a protein having a glycerol-3-phosphate dehydrogenase activity and a gene encoding a protein having a glycerol-3-phosphatase activity. In addition to the G3PDH and G3P phosphatase genes, the host cell will contain disruptions in either or both of genes encoding endogenous glycerol kinase and glycerol dehydrogenase enzymes. The combined effect of the foreign G3PDH and G3P phosphatase genes (providing a pathway from the carbon source to glycerol) with the gene disruptions (blocking the conversion of glycerol) results in an organism that is capable of efficient and reliable glycerol production.

Although the optimal organism for glycerol production contains the above mentioned gene disruptions, glycerol production is possible with a host cell containing either one or both of the foreign G3PDH and G3P phosphatase genes in the absence of such disruptions. For example, the recombinant *E. coli* strain AA200 carrying the DAR1 gene (Example 1) was capable of producing between 0.38 g/L and 0.48 g/L of glycerol depending on fermentation parameters. Similarly, the *E. coli* DH5 α , carrying and expressible GPP2 gene (Example 2), was capable of 0.2 g/L of glycerol production. Where both genes are present, (Example 3 and 4), glycerol production attained about 40 g/L. Where both genes are present in conjunction with an elimination of the endogenous glycerol kinase activity, a reduction in the conversion of glycerol may be seen (Example 8). Furthermore, the presence of glycerol dehydrogenase activity is linked to the conversion of glycerol under glucose-limited conditions; thus, it is anticipated that the elimination of glycerol dehydrogenase activity will result in the reduction of glycerol conversion (Example 8).

Production of 1,3-propanediol

The present invention may also be adapted for the production of 1,3-propanediol by utilizing recombinant organisms expressing the foreign G3PDH and/or G3P phosphatase genes and containing disruptions in the endogenous glycerol kinase and/or glycerol dehydrogenase activities.

Additionally, the invention provides for the process for the production of 1,3-propanediol from a recombinant organism where multiple copies of endogeneous genes are introduced. In addition to these genetic alterations, the production cell will require the presence of a gene encoding an active 5 dehydratase enzyme. The dehydratase enzyme activity may either be a glycerol dehydratase or a diol dehydratase. The dehydratase enzyme activity may result from either the expression of an endogenous gene or from the expression of a foreign gene transfected into the host organism. Isolation and expression of genes encoding suitable dehydratase enzymes are well known in the art and are 10 taught by applicants in PCT/US96/06705, filed 5 November 1996 and U.S. 5686276 and U.S. 5633362, hereby incorporated by reference. It will be appreciated that, as glycerol is a key intermediate in the production of 1,3-propanediol, where the host cell contains a dehydratase activity in conjunction with expressed foreign G3PDH and/or G3P phosphatase genes and 15 in the absence of the glycerol-converting glycerol kinase or glycerol dehydrogenase activities, the cell will be particularly suited for the production of 1,3-propanediol.

The present invention is further defined in the following Examples. It should be understood that these Examples, while indicating preferred embodiments of the invention, are given by way of illustration only. From the above discussion and these Examples, one skilled in the art can ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.

25

30

35

20

EXAMPLES

GENERAL METHODS

Procedures for phosphorylations, ligations, and transformations are well known in the art. Techniques suitable for use in the following examples may be found in Sambrook et al., <u>Molecular Cloning</u>: <u>A Laboratory Manual</u>, Second Edition, Cold Spring Harbor Laboratory Press (1989).

Materials and methods suitable for the maintenance and growth of bacterial cultures are well known in the art. Techniques suitable for use in the following examples may be found in Manual of Methods for General

Bacteriology (Phillipp Gerhardt, R. G. E. Murray, Ralph N. Costilow, Eugene W. Nester, Willis A. Wood, Noel R. Krieg and G. Briggs Phillips, eds), American Society for Microbiology, Washington, DC. (1994) or in

Biotechnology: A Textbook of Industrial Microbiology (Thomas D. Brock, Second Edition (1989) Sinauer Associates, Inc., Sunderland, MA). All reagents and materials used for the growth and maintenance of bacterial cells were

obtained from Aldrich Chemicals (Milwaukee, WI), DIFCO Laboratories (Detroit, MI), GIBCO/BRL (Gaithersburg, MD), or Sigma Chemical Company (St. Louis, MO) unless otherwise specified.

The meaning of abbreviations is as follows: "h" means hour(s), "min" means minute(s), "sec" means second(s), "d" means day(s), "mL" means milliliters, "L" means liters.

Cell strains

5

10

20

40

The following *Escherichia coli* strains were used for transformation and expression of G3PDH and G3P phosphatase. Strains were obtained from the *E. coli* Genetic Stock Center, ATCC, or Life Technologies (Gaithersburg, MD).

AA200 (garB10 fhuA22 ompF627 fadL701 relA1 pit-10 spoT1 tpi-1 phoM510 mcrB1) (Anderson et al., (1970), J. Gen. Microbiol., 62:329).

BB20 (tonA22 ΔphoA8 fadL701 relA1 glpR2 glpD3 pit-10 gpsA20 spoT1 T2R) (Cronan et al., J. Bact., 118:598).

DH5 α (deoR endA1 gyrA96 hsdR17 recA1 relA1 supE44 thi-1 Δ (lacZYA-argFV169) phi80lacZ Δ M15 F⁻) (Woodcock et al., (1989), Nucl. Acids Res., 17:3469).

FM5 Escherichia coli (ATCC 53911)

Identification of Glycerol

- The conversion of glucose to glycerol was monitored by HPLC and/or GC. Analyses were performed using standard techniques and materials available to one of skill in the art of chromatography. One suitable method utilized a Waters Maxima 820 HPLC system using UV (210 nm) and RI detection. Samples were injected onto a Shodex SH-1011 column (8 mm x 300 mm;
- Waters, Milford, MA) equipped with a Shodex SH-1011P precolumn (6 mm x 50 mm), temperature-controlled at 50 °C, using 0.01 N H₂SO₄ as mobile phase at a flow rate of 0.69 mL/min. When quantitative analysis was desired, samples were prepared with a known amount of trimethylacetic acid as an external standard. Typically, the retention times of 1,3-propanediol (RI detection),
- 35 glycerol (RI detection) and glucose (RI detection) were 21.39 min, 17.03 min and 12.66 min, respectively.

Glycerol was also analyzed by GC/MS. Gas chromatography with mass spectrometry detection for separation and quantitation of glycerol was performed using a DB-WAX column (30 m, 0.32 mm I.D., 0.25 um film thickness, J & W Scientific, Folsom, CA) at the following conditions: injector: split, 1:15;

sample volume: 1 uL; temperature profile: 150 °C intitial temperature with 30 sec hold, 40 °C/min to 180 °C, 20 °C/min to 240 °C, hold for 2.5 min. Detection: EI Mass Spectrometry (Hewlett Packard 5971, San Fernando, CA), quantitative SIM using ions 61 m/z and 64 m/z as target ions for glycerol and glycerol-d8, and ion 43 m/z as qualifier ion for glycerol. Glycerol-d8 was used as an internal standard.

Assay for glycerol-3-phosphatase, G3P phosphatase

5

10

15

20

25

30

35

The assay for enzyme activity was performed by incubating the extract with an organic phosphate substrate in a bis-Tris or MES and magnesium buffer. pH 6.5. The substrate used was either $1-\alpha$ -glycerol phosphate, or d, $1-\alpha$ -glycerol phosphate. The final concentrations of the reagents in the assay are: buffer (20 mM bis-Tris or 50 mM MES); MgCl₂ (10 mM); and substrate (20 mM). If the total protein in the sample was low and no visible precipitation occurs with an acid quench, the sample was conveniently assayed in the cuvette. This method involved incubating an enzyme sample in a cuvette that contained 20 mM substrate (50 μ L, 200 mM), 50 mM MES, 10 mM MgCl₂, pH 6.5 buffer. The final phosphatase assay volume was 0.5 mL. The enzymecontaining sample was added to the reaction mixture; the contents of the cuyette were mixed and then the cuvette was placed in a circulating water bath at T = 37 °C for 5 to 120 min, the length of time depending on whether the phosphatase activity in the enzyme sample ranged from 2 to 0.02 U/mL. The enzymatic reaction was quenched by the addition of the acid molybdate reagent (0.4 mL). After the Fiske SubbaRow reagent (0.1 mL) and distilled water (1.5 mL) were added, the solution was mixed and allowed to develop. After 10 min, to allow full color development, the absorbance of the samples was read at 660 nm using a Cary 219 UV/Vis spectrophotometer. The amount of inorganic phosphate released was compared to a standard curve that was prepared by using a stock inorganic phosphate solution (0.65 mM) and preparing 6 standards with final inorganic phosphate concentrations ranging from 0.026 to $0.130 \mu mol/mL$.

Spectrophotometric Assay for Glycerol 3-Phosphate Dehydrogenase (G3PDH) Activity

The following procedure was used as modified below from a method published by Bell et al. (1975), *J. Biol. Chem.*, 250:7153-8. This method involved incubating an enzyme sample in a cuvette that contained 0.2 mM NADH; 2.0 mM dihydroxyacetone phosphate (DHAP), and enzyme in 0.1 M Tris/HCl, pH 7.5 buffer with 5 mM DTT, in a total volume of 1.0 mL at 30 °C. The spectrophotometer was set to monitor absorbance changes at the fixed wavelength of 340 nm. The instrument was blanked on a cuvette containing

buffer only. After the enzyme was added to the cuvette, an absorbance reading was taken. The first substrate, NADH (50 uL 4 mM NADH; absorbance should increase approx 1.25 AU), was added to determine the background rate. The rate should be followed for at least 3 min. The second substrate, DHAP (50 uL 40 mM DHAP), was then added and the absorbance change over time was monitored for at least 3 min to determine to determine the gross rate. G3PDH activity was defined by subtracting the background rate from the gross rate. 13C-NMR Assay for Glycerol Kinase Activity

An appropriate amount of enzyme, typically a cell-free crude extract, was added to a reaction mixture containing 40 mM ATP, 20 mM MgSO₄, 21 mM uniformly 13 C labelled glycerol (99%, Cambridge Isotope Laboratories), and 0.1 M Tris-HCl, pH 9 for 75 min at 25 °C. The conversion of glycerol to glycerol 3-phosphate was detected by 13 C-NMR (125 MHz): glycerol (63.11 ppm, d, $J = ^{41}$ Hz and 72.66 ppm, t, $J = ^{41}$ Hz); glycerol 3-phosphate (62.93 ppm, d, $J = ^{41}$ Hz; 65.31 ppm, br d, $J = ^{43}$ Hz; and 72.66 ppm, dt, $J = ^{6}$, 41 Hz).

NADH-linked Glycerol Dehydrogenase Assay

5

10

15

20

35

NADH -linked glycerol dehydrogenase activity in *E. coli* strains (*gldA*) was determined after protein separation by non-denaturing polyacrylamide gel electrophoresis. The conversion of glycerol plus NAD+ to dihydroxyacetone plus NADH was coupled with the conversion of 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) to a deeply colored formazan, using phenazine methosulfate (PMS) as mediator. (Tang et al. (1997) *J. Bacteriol*. 140:182).

Electrophoresis was performed in duplicate by standard procedures using native gels (8-16% TG, 1.5 mm, 15 lane gels from Novex, San Diego, CA).

Residual glycerol was removed from the gels by washing 3x with 50 mM Tris or potassium carbonate buffer, pH 9 for 10 min. The duplicate gels were developed, with and without glycerol (approx. 0.16 M final concentration), in 15 mL of assay solution containing 50 mM Tris or potassium carbonate, pH 9, 60 mg ammonium sûlfate, 75 mg NAD+, 1.5 mg MTT, and 0.5 mg PMS.

The presence or absence of NADH -linked glycerol dehydrogenase activity in *E. coli* strains (*gldA*) was also determined, following polyacrylamide gel electrophoresis, by reaction with polyclonal antibodies raised to purified *K. pneumoniae* glycerol dehydrogenase (*dhaD*).

PLASMID CONSTRUCTION AND STRAIN CONSTRUCTION Cloning and expression of glycerol 3-phosphatase for increase of glycerol production in E. coli DH5α and FM5

The Saccharomyces cerevisiae chromosomeV lamda clone 6592 (Gene Bank, accession # U18813x11) was obtained from ATCC. The glycerol 3-phosphate phosphatase (GPP2) gene was cloned by cloning from the lamda clone as target DNA using synthetic primers (SEQ ID NO:16 with SEQ ID NO:17) incorporating an BamHI-RBS-XbaI site at the 5' end and a SmaI site at the 3' end. The product was subcloned into pCR-Script (Stratagene, Madison, WI) at the SrfI site to generate the plasmids pAH15 containing GPP2. The plasmid pAH15 contains the GPP2 gene in the inactive orientation for expression from the lac promoter in pCR-Script SK+. The BamHI-SmaI fragment from pAH15 containing the GPP2 gene was inserted into pBlueScriptII SK+ to generate plasmid pAH19. The pAH19 contains the GPP2 gene in the correct orientation for expression from the lac promoter. The XbaI-PstI fragment from pAH19 containing the GPP2 gene was inserted into pPHOX2 to

create plasmid pAH21. The pAH21/ DH5 α is the expression plasmid. Plasmids for the over-expression of DAR1 in E. coli

DAR1 was isolated by PCR cloning from genomic S. cerevisiae DNA
using synthetic primers (SEQ ID NO:18 with SEQ ID NO:19). Successful PCR
cloning places an NcoI site at the 5' end of DAR1 where the ATG within NcoI
is the DAR1 initiator methionine. At the 3' end of DAR1 a BamHI site is
introduced following the translation terminator. The PCR fragments were
digested with NcoI + BamHI and cloned into the same sites within the
expression plasmid pTrc99A (Pharmacia, Piscataway, NJ) to give pDAR1A.

In order to create a better ribosome binding site at the 5' end of DAR1, an SpeI-RBS-NcoI linker obtained by annealing synthetic primers (SEQ ID NO:20 with SEQ ID NO:21) was inserted into the NcoI site of pDAR1A to create pAH40. Plasmid pAH40 contains the new RBS and DAR1 gene in the correct orientation for expression from the trc promoter of pTrc99A (Pharmacia, Piscataway, NJ). The NcoI-BamHI fragement from pDAR1A and an second set of SpeI-RBS-NcoI linker obtained by annealing synthetic primers (SEQ ID NO:22 with SEQ ID NO:23) was inserted into the SpeI-BamHI site of pBC-SK+ (Stratagene, Madison, WI) to create plasmid pAH42. The plasmid pAH42 contains a chloramphenicol resistant gene.

Construction of expression cassettes for DAR1 and GPP2

30

35

Expression cassettes for DAR1 and GPP2 were assembled from the individual DAR1 and GPP2 subclones described above using standard molecular biology methods. The BamHI-PstI fragment from pAH19 containing the

ribosomal binding site (RBS) and GPP2 gene was inserted into pAH40 to create pAH43. The BamHI-PstI fragment from pAH19 containing the RBS and GPP2 gene was inserted into pAH42 to create pAH45.

The ribosome binding site at the 5' end of GPP2 was modified as follows. A BamHI-RBS-SpeI linker, obtained by annealing synthetic primers GATCCAGGAAACAGA (SEQ ID NO:24) with CTAGTCTGTTTCCTG (SEQ ID NO:25) to the XbaI-PstI fragment from pAH19 containing the GPP2 gene, was inserted into the BamHI-PstI site of pAH40 to create pAH48. Plasmid pAH48 contains the DAR1 gene, the modified RBS, and the GPP2 gene in the correct orientation for expression from the trc promoter of pTrc99A (Pharmacia, Piscataway, NJ).

Transformation of E. coli

All the plasmids described here were transformed into E. coli DH5 α or FM5 using standard molecular biology techniques. The transformants were verified by its DNA RFLP pattern.

EXAMPLE 1 PRODUCTION OF GLYCEROL FROM E. COLI TRANSFORMED WITH G3PDH GENE

Media

5

10

15

30

Synthetic media was used for anaerobic or aerobic production of glycerol using *E. coli* cells transformed with pDAR1A. The media contained per liter 6.0 g Na₂HPO₄, 3.0 g KH₂PO₄, 1.0 g NH₄Cl, 0.5 g NaCl, 1 mL 20% MgSO₄.7H₂O, 8.0 g glucose, 40 mg casamino acids, 0.5 ml 1% thiamine hydrochloride, 100 mg ampicillin.

25 Growth Conditions

Strain AA200 harboring pDAR1A or the pTrc99A vector was grown in aerobic conditions in 50 mL of media shaking at 250 rpm in 250 mL flasks at 37 °C. At A_{600} 0.2-0.3 isopropylthio- β -D-galactoside was added to a final concentration of 1 mM and incubation continued for 48 h. For anaerobic growth samples of induced cells were used to fill Falcon #2054 tubes which were capped and gently mixed by rotation at 37 °C for 48 h. Glycerol production was determined by HPLC analysis of the culture supernatants. Strain pDAR1A/AA200 produced 0.38 g/L glycerol after 48 h under anaerobic conditions, and 0.48 g/L under aerobic conditions.

<u>EXAMPLE 2</u> <u>PRODUCTION OF GLYCEROL FROM E. COLI</u> TRANSFORMED WITH G3P PHOSPHATASE GENE (GPP2)

Media

5

10

20

25

30

35

Synthetic phoA media was used in shake flasks to demonstrate the increase of glycerol by GPP2 expression in *E. coli*. The phoA medium contained per liter: Amisoy, 12 g; ammonium sulfate, 0.62 g; MOPS, 10.5 g; Na-citrate, 1.2 g; NaOH (1 M), 10 mL; 1 M MgSO₄, 12 mL; 100X trace elements, 12 mL; 50% glucose, 10 mL; 1% thiamine, 10 mL; 100 mg/mL L-proline, 10 mL; 2.5 mM FeCl₃, 5 mL; mixed phosphates buffer, 2 mL (5 mL 0.2 M NaH₂PO₄+ 9 mL 0.2 M K₂HPO₄), and pH to 7.0. The 100X traces elements for phoA medium /L contained: ZnSO₄·7 H₂O, 0.58 g; MnSO₄·H₂O, 0.34 g; CuSO₄·5 H₂O, 0.49 g; CoCl₂·6 H₂O, 0.47 g; H₃BO₃, 0.12 g, NaMoO₄·2 H₂O, 0.48 g.

15 Shake Flasks Experiments

The strains pAH21/DH5 α (containing GPP2 gene) and pPHOX2/DH5 α (control) were grown in 45 mL of media (phoA media, 50 ug/mL carbenicillin, and 1 ug/mL vitamin B₁₂) in a 250 mL shake flask at 37 °C. The cultures were grown under aerobic condition (250 rpm shaking) for 24 h. Glycerol production was determined by HPLC analysis of the culture supernatant. pAH21/DH5 α produced 0.2 g/L glycerol after 24 h.

EXAMPLE 3

PRODUCTION OF GLYCEROL FROM D-GLUCOSE USING RECOMBINANT E. COLI CONTAINING BOTH GPP2 AND DAR1

Growth for demonstration of increased glycerol production by $E.\ coli$ DH5 α -containing pAH43 proceeds aerobically at 37 °C in shake-flask cultures (erlenmeyer flasks, liquid volume 1/5th of total volume).

Cultures in minimal media/1% glucose shake-flasks are started by inoculation from overnight LB/1% glucose culture with antibiotic selection. Minimal media are: filter-sterilized defined media, final pH 6.8 (HCl), contained per liter: 12.6 g (NH₄)₂SO₄, 13.7 g K₂HPO₄, 0.2 g yeast extract (Difco), 1 g NaHCO₃, 5 mg vitamin B₁₂, 5 mL Modified Balch's Trace-Element Solution (the composition of which can be found in Methods for General and Molecular Bacteriology (P. Gerhardt et al., eds, p. 158, American Society for Microbiology, Washington, DC (1994)). The shake-flasks are incubated at 37 °C with vigorous shaking for overnight, after which they are sampled for GC analysis of the supernatant. The pAH43/DH5α showed glycerol production of 3.8 g/L after 24 h.

EXAMPLE 4

PRODUCTION OF GLYCEROL FROM D-GLUCOSE USING RECOMBINANT E. COLI CONTAINING BOTH GPP2 AND DAR1

Example 4 illustrates the production of glucose from the recombinant

5 E. coli DH5α/pAH48, containing both the GPP2 and DAR1 genes.

The strain DH5a/pAH48 was constructed as described above in the GENERAL METHODS.

Pre-Culture

DH5α/pAH48 were pre-cultured for seeding into a fermentation run.

10 Components and protocols for the pre-culture are listed below.

Pre-Culture Media

	KH ₂ PO ₄	30.0 g/L
	Citric acid	2.0 g/L
	MgSO ₄ ·7H ₂ O	2.0 g/L
15	98% H ₂ SO ₄	2.0 mL/L
	Ferric ammonium citrate	0.3 g/L
	CaCl ₂ ·2H ₂ O	0.2 g/L
	Yeast extract	5.0 g/L
	Trace metals	5.0 mL/L
20	Glucose	10.0 g/L
	Carbenicillin	100.0 mg/L

The above media components were mixed together and the pH adjusted to 6.8 with NH₄OH. The media was then filter sterilized.

Trace metals were used according to the following recipe:

25	Citric acid, monohydrate	4.0 g/L
	MgSO ₄ ·7H ₂ O	3.0 g/L
	MnSO4·H ₂ O	0.5 g/L
	NaCl	1.0 g/L
	FeSO4·7H ₂ O	0.1 g/L
30	CoCl2·6H ₂ O	0.1 g/L
	CaCl ₂	0.1 g/L
	ZnSO ₄ ·7H ₂ O	0.1 g/L
	CuSO ₄ ·5 H ₂ O	10 mg/L
	$AlK(SO_4)_2 \cdot 12H_2O$	10 mg/L
35	H ₃ BO ₃	10 mg/L
	Na ₂ MoO ₄ ·2H ₂ O	10 mg/L
	NiSO4·6H ₂ O	10 mg/L
	Na ₂ SeO ₃	10 mg/L
	Na ₂ WO ₄ ·2H ₂ O	10 mg/L

Cultures were started from seed culture inoculated from $50~\mu L$ frozen stock (15% glycerol as cryoprotectant) to 600 mL medium in a 2-L Erlenmeyer flask. Cultures were grown at 30 °C in a shaker at 250 rpm for approximately 12 h and then used to seed the fermenter.

5 Fermentation growth

Vessel

15-L stirred tank fermenter

Medium

25

	KH ₂ PO ₄	6.8 g/L
10	Citric acid	2.0 g/L
	MgSO ₄ ·7H ₂ O	2.0 g/L
	98% H ₂ SO ₄	2.0 mL/L
	Ferric ammonium citrate	0.3 g/L
	CaCl ₂ ·2H ₂ C	0.2 g/L
15	Mazu DF204 antifoam	1.0 mL/L

The above components were sterilized together in the fermenter vessel. The pH was raised to 6.7 with NH₄OH. Yeast extract (5 g/L) and trace metals solution (5 mL/L) were added aseptically from filter sterilized stock solutions. Glucose was added from 60% feed to give final concentration of 10 g/L.

20 Carbenicillin was added at 100 mg/L. Volume after inoculation was 6 L. Environmental Conditions For Fermentation

The temperature was controlled at 36 °C and the air flow rate was controlled at 6 standard liters per minute. Back pressure was controlled at 0.5 bar. The agitator was set at 350 rpm. Aqueous ammonia was used to control pH at 6.7. The glucose feed (60% glucose monohydrate) rate was controlled to maintain excess glucose.

Results

The results of the fermentation run are given in Table 1.

			Table 1		
EFT (hr)	OD550 (AU)	[Glucose] (g/L)	[Glycerol] (g/L)	Total Glucose Fed (g)	Total Glycerol Produced (g)
0	0.8	9.3		25	
6	4.7	4.0	2.0	49	14
8	5.4	0	3.6	71	25
10	6.7	0.0	4.7	116	33
12	7.4	2.1	7.0	157	49
14.2	10.4	0.3	10.0	230	70
16.2	18.1	9.7	15.5	259	106
18.2	12.4	14.5		305	
20.2	11.8	17.4	17.7	353	119
22.2	11.0	12.6		382	
24.2	10.8	∙ 6.5	26.6	404	178
26.2	10.9	6.8		442	
28.2	10.4	10.3	31.5	463	216
30.2	10.2	13.1	30.4	493	213
32.2	10.1	8.1	28.2	512	196
34.2	10.2	3.5	33.4	530	223
36.2	10.1	5.8		548	
38.2	9.8	5.1	36.1	512	233

5 EXAMPLE 5

ENGINEERING OF GLYCEROL KINASE MUTANTS OF E. COLI FM5 FOR PRODUCTION OF GLYCEROL FROM GLUCOSE

Construction of integration plasmid for glycerol kinase gene replacement in E. coli FM5

E. coli FM5 genomic DNA was prepared using the Puregene DNA Isolation Kit (Gentra Systems, Minneapolis, MN). A 1.0 kb DNA fragment containing partial glpF and glycerol kinase (glpK) genes was amplified by PCR (Mullis and Faloona, Methods Enzymol., 155:335-350, 1987) from FM5 genomic DNA using primers SEQ ID NO:26 and SEQ ID NO:27. A 1.1 kb
 DNA fragment containing partial glpK and glpX genes was amplified by PCR from FM5 genomic DNA using primers SEQ ID NO:28 and SEQ ID NO:29. A MunI site was incorporated into primer SEQ ID NO:28. The 5' end of primer SEQ ID NO:28 was the reverse complement of primer SEQ ID NO:27 to enable

subsequent overlap extension PCR. The gene splicing by overlap extension technique (Horton et al., *BioTechniques*, 8:528-535, 1990) was used to generate a 2.1 kb fragment by PCR using the above two PCR fragments as templates and primers SEQ ID NO:26 and SEQ ID NO:29. This fragment represented a deletion of 0.8 kb from the central region of the 1.5 kb *glpK* gene. Overall, this fragment had 1.0 kb and 1.1 kb flanking regions on either side of the *MunI* cloning site (within the partial *glpK*) to allow for chromosomal gene replacement by homologous recombination.

5

30

35

The above 2.1 kb PCR fragment was blunt-ended (using mung bean 10 nuclease) and cloned into the pCR-Blunt vector using the Zero Blunt PCR Cloning Kit (Invitrogen, San Diego, CA) to yield the 5.6 kb plasmid pRN100 containing kanamycin and Zeocin resistance genes. The 1.2 kb HincII fragment from pLoxCat1 (unpublished results), containing a chloramphenicol-resistance gene flanked by bacteriophage P1 loxP sites (Snaith et al., Gene. 166:173-174) 15 1995), was used to interrupt the glpK fragment in plasmid pRN100 by ligating it to MunI-digested (and blunt-ended) plasmid pRN100 to yield the 6.9 kb plasmid pRN101-1. A 376 bp fragment containing the R6K origin was amplified by PCR from the vector pGP704 (Miller and Mekalanos, J. Bacteriol., 170:2575-2583, 1988) using primers SEQ ID NO:30 and SEQ ID NO:31, blunt-20 ended, and ligated to the 5.3 kb Asp718-AatII fragment (which was bluntended) from pRN101-1 to yield the 5.7 kb plasmid pRN102-1 containing kanamycin and chloramphenicol resistance genes. Substitution of the ColE1 origin region in pRN101-1 with the R6K origin to generate pRN102-1 also involved deletion of most of the Zeocin resistance gene. The host for pRN102-1 25 replication was E. coli SY327 (Miller and Mekalanos, J. Bacteriol... 170:2575-2583, 1988) which contains the pir gene necessary for the function of the R6K origin.

Engineering Of Glycerol Kinase Mutant RJF10m With Chloramphenicol Resistance Gene Interrupt

E. coli FM5 was electrotransformed with the non-replicative integration plasmid pRN102-1 and transformants that were chloramphenicol-resistant (12.5 μg/mL) and kanamycin-sensitive (30 μg/mL) were further screened for glycerol non-utilization on M9 minimal medium containing 1 mM glycerol. An EcoRI digest of genomic DNA from one such mutant, RJF10m, when probed with the intact glpK gene via Southern analysis (Southern, J. Mol. Biol., 98:503-517, 1975) indicated that it was a double-crossover integrant (glpK gene replacement) since the two expected 7.9 kb and 2.0 kb bands were observed, owing to the presence of an additional EcoRI site within the chloramphenicol resistance gene. The wild-type control yielded the single expected 9.4 kb band.

A ¹³C NMR analysis of mutant RJF10m confirmed that it was incapable of converting ¹³C-labeled glycerol and ATP to glycerol-3-phosphate. This *glpK* mutant was further analyzed by genomic PCR using primer combinations SEQ ID NO:32 and SEQ ID NO:33, SEQ ID NO:34 and SEQ ID NO:35, and SEQ ID NO:35 which yielded the expected 2.3 kb, 2.4 kb, and 4.0 kb PCR fragments respectively. The wild-type control yielded the expected 3.5 kb band with primers SEQ ID NO:32 and SEQ ID NO:35. The *glpK* mutant RJF10m was electrotransformed with plasmid pAH48 to allow glycerol production from glucose. The *glpK* mutant *E. coli* RJF10m has been deposited with ATCC under the terms of the Budapest Treaty on 24 November 1997. Engineering Of Glycerol Kinase Mutant RJF10 With Chloramphenicol Resistance Gene Interrupt Removed

5

10

After overnight growth on YENB medium (0.75% yeast extract, 0.8% nutrient broth) at 37 °C, E. coli RJF10m in a water suspension was 15 electrotransformed with plasmid pJW168 (unpublished results), which contained the bacteriophage P1 Cre recombinase gene under the control of the IPTGinducible lacUV5 promoter, a temperature-sensitive pSC101 replicon, and an ampicillin resistance gene. Upon outgrowth in SOC medium at 30 °C. transformants were selected at 30 °C (permissive temperature for pJW168 20 replication) on LB agar medium supplemented with carbenicillin (50 µg/mL) and IPTG (1 mM). Two serial overnight transfers of pooled colonies were carried out at 30 °C on fresh LB agar medium supplemented with carbenicillin and IPTG in order to allow excision of the chromosomal chloramphenicol resistance gene via recombination at the loxP sites mediated by the Cre recombinase (Hoess and Abremski, J. Mol. Biol., 181:351-362, 1985). Resultant colonies 25 were replica-plated on to LB agar medium supplemented with carbenicillin and PTG and LB agar supplemented with chloramphenical (12.5 µg/mL) to identify colonies that were carbenicillin-resistant and chloramphenicol-sensitive indicating marker gene removal. An overnight 30 °C culture of one such colony 30 was used to inoculate 10 mL of LB medium. Upon growth at 30 °C to OD (600 nm) of 0.6, the culture was incubated at 37 °C overnight. Several dilutions were plated on prewarmed LB agar medium and the plates incubated overnight at 42 °C (the non-permissive temperature for pJW168 replication). Resultant colonies were replica-plated on to LB agar medium and LB agar medium 35 supplemented with carbenicillin (75 µg/mL) to identify colonies that were carbenicillin-sensitive indicating loss of plasmid pJW168. One such glpK mutant, RJF10, was further analyzed by genomic PCR using primers SEO ID NO:32 and SEQ ID NO:35 and yielded the expected 3.0 kb band confirming marker gene excision. Glycerol non-utilization by mutant RJF10 was confirmed

by lack of growth on M9 minimal medium containing 1 mM glycerol. The *glpK* mutant RJF10 was electrotransformed with plasmid pAH48 to allow glycerol production from glucose.

EXAMPLE 6

5 CONSTRUCTION OF E. COLI STRAIN WITH GLDA GENE KNOCKOUT

10

15

20

25

30

35

The gldA gene was isolated from E. coli by PCR (K. B. Mullis and F. A. Faloona (1987) Meth. Enzymol. 155:335-350) using primers SEQ ID NO:36 and SEQ ID NO:37, which incorporate terminal Sph1 and Xba1 sites. respectively, and cloned (T. Maniatis 1982 Molecular Cloning. A Laboratory Manual. Cold Spring Harbor, Cold Spring Harbor, NY) between the Sph1 and Xba1 sites in pUC18, to generate pKP8. pKP8 was cut at the unique Sal1 and Ncol sites within the gldA gene, the ends flushed with Klenow and religated, resulting in a 109 bp deletion in the middle of gldA and regeneration of a unique Sall site, to generate pKP9. A 1.4 kb DNA fragment containing the gene conferring kanamycin resistance (kan), and including about 400 bps of DNA upstream of the translational start codon and about 100 bps of DNA downstream of the translational stop codon, was isolated from pET-28a(+) (Novagen, Madison, Wis) by PCR using primers SEQ ID NO:38 and SEQ ID NO:39, which incorporate terminal Sal1 sites, and subcloned into the unique Sal1 site of pKP9, to generate pKP13. A 2.1 kb DNA fragment beginning 204 bps downstream of the gldA translational start codon and ending 178 bps upstream of the gldA translational stop codon, and containing the kan insertion, was isolated from pKP13 by PCR using primers SEQ ID NO:40 and SEQ ID NO:41, which incorporate terminal Sph1 and Xba1 sites, respectively, was subcloned between the Sph1 and Xba1 sites in pMAK705 (Genencor International, Palo Alto, Calif.), to generate pMP33. E. coli FM5 was transformed with pMP33 and selected on 20 ug/mL kan at 30 °C, which is the permissive temperature for pMAK705 replication. One colony was expanded overnight at 30 °C in liquid media supplemented with 20 ug/mL kan. Approximately 32,000 cells were plated on 20 ug/mL kan and incubated for 16 hrs at 44 °C, which is the restrictive temperature for pMAK705 replication. Transformants growing at 44 °C have plasmid integrated into the chromosome, occuring at a frequency of approximately 0.0001. PCR and Southern blot (E.M. Southern 1975 J. Mol. Biol. 98:503-517) analyses were used to determine the nature of the chromosomal integration events in the transformants. Western blot analysis (H. Towbin, et al. (1979) Proc. Natl. Acad. Sci. 76:4350) was used to determine whether glycerol dehydrogenase protein, the product of gldA, is produced in the transformants. An activity assay was used to determine whether

glycerol dehydrogenase activity remained in the transformants. Activity in

glycerol dehydrogenase bands on native gels was determined by coupling the conversion of glycerol + NAD(+) \rightarrow dihydroxyacetone + NADH to the conversion of a tetrazolium dye, MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] to a deeply colored formazan, with phenazine methosulfate as mediator. Glycerol dehydrogenase also requires the presence of 30 mM ammonium sulfate and 100 mM Tris, pH 9 (C.-T. Tang, et al. (1997) *J. Bacteriol.* 140:182). Of 8 transformants analyzed, 6 were determined to be gldA knockouts. *E. coli* MSP33.6 has been deposited with ATCC under the terms of the Budapest Treaty on 24 November 1997.

10

5

EXAMPLE 7

CONSTRUCTION OF E. COLI STRAIN WITH GLPK AND GLDA GENE KNOCKOUTS

A 1.6 kb DNA fragment containing the gldA gene and including 228 bps of DNA upstream of the translational start codon and 220 bps of DNA 15 downstream of the translational stop codon was isolated from E. coli by PCR using primers SEQ ID NO:42 and SEQ ID NO:43, which incorporate terminal Sph1 and Xba1 sites, respectively, and cloned between the Sph1 and Xba1 sites of pUC18, to generate pON2. pON2 was cut at the unique Sal1 and Nco1 sites within the gldA gene, the ends flushed with Klenow and religated, resulting in a 20 109 bps deletion in the middle of gldA and regeneration of a unique Sal1 site, to generate pQN4. A 1.2 kb DNA fragment containing the gene conferring kanamycin resistance (kan), and flanked by loxP sites was isolated from pLoxKan2 (Genencor International, Palo Alto, Calif.) as a Stu1/Xho1 fragment. the ends flushed with Klenow, and subcloned into pQN4 at the Sal1 site after 25 flushing with Klenow, to generate pQN8. A 0.4 kb DNA fragment containing the R6K origin of replication was isolated from pGP704 (Miller and Mekalanos, J. Bacteriol., 170:2575-2583, 1988) by PCR using primers SEO ID NO:44 and SEQ ID NO:45, which incorporate terminal Sph1 and Xba1 sites, respectively. and ligated to the 2.8 kb Sph1/Xba1 DNA fragment containing the gldA::kan 30 cassette from pQN8, to generate pKP22. A 1.0 kb DNA fragment containing the gene conferring chloramphenicol resistance (cam), and flanked by loxP sites was isolated from pLoxCat2 (Genencor International, Palo Alto, Calif.) as an Xba1 fragment, and subcloned into pKP22 at the Xba1 site, to generate pKP23. E. coli strain RJF10 (see EXAMPLE 5), which is glpK-, was transformed with pKP23 35 and transformants with the phenotype kanRcamS were isolated, indicating double crossover integration, which was confirmed by southern blot analysis. Glycerol dehydrogenase gel activity assays (as described in EXAMPLE 6) demonstrated that active glycerol dehydrogenase was not present in these transformants. The kan marker was removed from the chromosome using the Cre-producing plasmid

pJW168, as described in EXAMPLE 5, to produce strain KLP23. Several isolates with the phenotype kanS demonstrated no glycerol dehydrogenase activity, and southern blot analysis confirmed loss of the kan marker.

5 SEQ ID NO:44:

CACGCATGCAGTTCAACCTGTTGATAGTAC

SEQ ID NO:45:

GCGTCTAGATCCTTTTAAATTAAAAATG

10

EXAMPLE 8

CONSUMPTION OF GLYCEROL PRODUCED FROM D-GLUCOSE BY RECOMBINANT E. COLI CONTAINING BOTH GPP2 AND DAR1 WITH AND WITHOUT GLYCEROL KINASE (GLPK) ACTIVITY

EXAMPLE 8 illustrates the consumption of glycerol by the recombinant

E. coli FM5/pAH48 and RJF10/pAH48. The strains FM5/pAH48 and
RJF10/pAH48 were constructed as described above in the GENERAL
METHODS.

Pre-Culture

30

35

FM5/pAH48 and RJF10/pAH48 were pre-cultured for seeding a

20 fermenter in the same medium used for fermentation, or in LB supplemented with 1% glucose. Either carbenicillin or ampicillin were used (100 mg/L) for plasmid maintenance. The medium for fermentation is as described in EXAMPLE 4.

Cultures were started from frozen stocks (15% glycerol as

cryoprotectant) in 600 mL medium in a 2-L Erlenmeyer flask, grown at 30 °C in a shaker at 250 rpm for approximately 12 h, and used to seed the fermenter.

Fermentation growth

A 15-L stirred tank fermenter with 5-7 L initial volume was prepared as described in EXAMPLE 4. Either carbenicillin or ampicillin were used (100 mg/L) for plasmid maintenance.

Environmental Conditions to Evaluate Glycerol Kinase (GlpK) Activity

The temperature was controlled at 30 °C and the air flow rate controlled at 6 standard liters per minute. Back pressure was controlled at 0.5 bar. Dissolved oxygen tension was controlled at 10% by stirring. Aqueous ammonia was used to control pH at 6.7. The glucose feed (60% glucose) rate was controlled to maintain excess glucose until glycerol had accumulated to at least 25 g/L. Glucose was then depleted, resulting in the net metabolism of glycerol. Table 2 shows the resulting conversion of glycerol.

Table 2
Conversion of glycerol by FM5/pAH48 (wt) and RJF10/pAH48 (glpK)

Strain	number of examples	rate of glycero consumption g/OD/hr
FM5/pAH48	2	0.095 ± 0.015
RJF10/pAH48	3	0.021 ± 0.011

As is seen by the data in Table 2, the rate of glycerol consumption decreases about 4-5 fold where endogenous glycerol kinase activity is eliminated.

5 Environmental Conditions to Evaluate Glycerol Dehydrogenase (GldA) Activity

The temperature was controlled at 30 °C and the air flow rate controlled at 6 standard liters per minute. Back pressure was controlled at 0.5 bar. Dissolved oxygen tension was controlled at 10% by stirring. Aqueous ammonia was used to control pH at 6.7. In the first fermentation, glucose was kept in excess for the duration of the fermentation. The second fermentation was operated with no residual glucose after the first 25 hours. Samples over time from thetwo fermentations were taken for evaluation of GlpK and GldA activities. Table 3 summarizes RJF10/pAH48 fermentations that show the effects of GldA on selectivity for glycerol.

15

20

10

Table 3
GldA and GlpK activitities from two RJF10/pAH48 fermentations

Fermentation	Time (hrs)	GldA	GlpK	Overall selectivity (g/g)
1	25	-	-	42%
	46	-	-	49%
	61	+	-	54%
2	25	+	-	41%
	46	++	-	14%
	61	++	-	12%

As is seen by the data in Table 3, the presence of glycerol dehydrogenase (GldA) activity is linked to the conversion of glycerol under glucose-limited conditions; thus, it is anticipated that eliminating glycerol dehydrogenase activity will reduce glycerol conversion.

EXAMPLE 9

PRODUCTION OF GLYCEROL FROM D-GLUCOSE USING RECOMBINANT E. BLATTAE CONTAINING BOTH GPP2 AND DAR1

5 Example 9 illustrates the production of glycerol from D-glucose from recombinant *E. blattae* containing both GPP2 and DAR1 genes.

10

15

20

25

30

35

E. blattae, obtained from the ATCC and having ATCC accession number 33429, was grown at 30 °C until the culture reached an OD of about 0.6 AU at 600 nm. The culture was then transformed with pAH48, a plasmid comprising GPP2 and DAR1 genes (described in WO 98/21341), using electroporation techniques. The transformants were confirmed by DNA RFLP pattern and antibiotic resistance (200 ug/mL carbenicillin).

The transformed E. blattae was grown aerobically at 35 °C in shakeflask cultures. The cultures were grown in a defined medium plus 2% glucose with antibiotic selection and were started by inoculation from an overnight culture grown in LB plus 1% glucose with antibiotic selection. The defined medium contained per liter: 27.2 g KH₂PO₄, 2 g citric acid, 2 g MgSO₄·7H₂O, 1.2 ml 98% H₂SO₄, 0.3 g ferric ammonium citrate, 0.2 g CaCl₂ 2H₂O, 10 g yeast extract (Difco), 5 mL Modified Balch's Trace-Element Solution (the composition of which can be found in Methods for General and Molecular Bacteriology (P. Gerhardt et al., eds, p. 158, American Society for Microbiology, Washington, DC, (994)). The defined medium was filtersterilized and adjusted to a final pH 6.8 with NH₄OH. The shake-flasks were incubated at 35 °C overnight with vigorous shaking. The supernatant was then subjected to HPLC analysis for the presence of glycerol. After the overnight incubation, the E. blattae containing pAH48 produced 7.63 g/L of glycerol. The control, which was wild-type E. blattae (ATCC 33429) grown under the same conditions, produced = 0.2 g/L of glycerol.

EXAMPLE 10

PRODUCTION OF GLYCEROL FROM D-GLUCOSE

USING RECOMBINANT E. COLI DEFICIENT IN GLDA AND GLPK

AND CONTAINING BOTH GPP2 AND DAR1 INTEGRATED

INTO THE CHROMOSOME

This Example illustrates the production of glycerol from D glucose from recombinant *E. coli* with *gldA* and *glpK* gene knockouts and containing both GPP2 and DAR1 encoding genes integrated into the host cell chromosome.

E. coli strain KLP23, prepared as described in Example 7, is deficient in both glycerol kinase (product of glpK) and glycerol dehydrogenase (product of

gldA) activities. KLP23 containing DAR1, GPP2 and a loxP flanked chloramphenical resistant gene integrated into the chromosome at the ampC location was prepared and is referred to as AH76RIcm.

Integration plasmids were designed and constructed based on a cre-lox 5 integration system (Hoess, supra). In order to create the integration plasmids, a Hind III - Smal fragment of pLoxCat1 was inserted into Hind III and Sma I linearized pAH48 to create pAH48cm2. The pAH48 plasmid contains DAR1 and GPP2 genes expressed under the control of the trc promoter. The 3.5 kb ApaL I fragment of pAH48cm2 was blunt ended with T4 DNA polymerase (Boehringer Mannheim Biochemical) and dNTPs and inserted into NruI 10 linearized pInt-ampC (Genencor International, CA), using E coli SY327 (Miller et al., J. Bacteriol. 170:2575-2583, 1998) as a host to create pAH76 and pAH76R. The "R" means reverse orientation of the integration cassette. Both plasmids, pAH76 and pAH76R, contain a R6K origin of replication and are not 15 able to replicate in KLP23. The plasmids pAH76 and pAH76R were used to transform KLP23 for integration at the ampC location of the E. coli chromosome. The transformants were selected on 10 ug/ml of chloramphenicol and were kanamycin sensitive, yielding double crossover integration. These E. coli transformants are named AH76Icm and AH76RIcm.

AH76RIcm cultures were grown in shake-flasks in defined medium (described in Example 9) plus 2.5% glucose started by inoculation from an overnight LB culture having 1% glucose and antibiotic selection. The shake-flasks (erlenmeyer flasks, liquid volume 1/5th of total volume) were incubated at 37 °C with vigorous shaking overnight, after which the supernatant was sampled for glycerol using a colormetric enzyme assay (Sigma, Procedure No. 337) on a Monarch 2000 instrument (Instrumentation Laboratory Co., Lexington, MA). AH77RIcm showed glycerol production of 6.7 g/L after 25 hr.

20

25

30

35

E. coli pAH76RI has the chloramphenicol gene deleted from AH76RIcm. The chloramphenicol gene was deleted from the chromosome using the Cre-producing plasmid, pJW168, as described in Example 5. The transformants were selected for carbenicillin resistance and chloramphenicol sensitivity under 1 mM IPTG induction at 30 °C. After removal of the chloramphenicol gene, AH76RI was grown on LB medium without any antibiotics to cure pJW168. The final version of AH76RI is not able to grow on chloramphenicol or carbenicillin selection.

AH76RI cultures were grown in shake-flasks in a defined media plus 2% glucose started by inoculation from an overnight LB/1% glucose culture. The shake-flasks were incubated at 35 °C with vigorous shaking overnight, after which the supernatant was sampled for glycerol using a colormetric assay

(Sigma, Procedure No. 337) on a Monarch 2000 instrument (Instrumentation Laboratory Co. Lexington, MA). AH77RI showed glycerol production of 4.6 g/L after 24 hr.

All the plasmids described in this example were transformed into 5 E. coli KLP23 using standard molecular biology techniques. The transformants were verified by DNA RFLP pattern, antibiotic resistance, PCR amplification, or G3P phosphatase assay.

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referron page5, line20	ed to in the description
B. IDENTIFICATION OF DEPOSIT	Further deposits are identified on an additional sheet
Name of depositary institution AMERICAN TYPE CULTURE COLLECTION	
Address of depositary institution (including postal code and country	ער
10801 University Blvd. Manassas, Virginia 20110-2209 USA	
Date of deposit	Accession Number
26 September 1996	ATCC98187
C. ADDITIONAL INDICATIONS (leave blank if not applicable	This information is continued on an additional sheet
In respect of those designations in which a sample of the deposited microorganism the publication of the mention of the quantil the date on which the application or is deemed to be withdrawn, only by expert nominated by the person requests	will be made available until grant of the European patent or has been refused or withdrawn the issue of such a sample to an
D. DESIGNATED STATES FOR WHICH INDICATIONS A	RE MADE (if the indications are not for all designated States)
•	
E. SEPARATE FURNISHING OF INDICATIONS (leave blan	k if not applicable)
The indications listed below will be submitted to the International E Number of Deposit")	Bureau later (specify the general nature of the indications e.g., "Accession
For receiving Office use only	For International Bureau use only
This sheet was received with the international application	This sheet was received by the International Bureau on:
Authorized officer Ministration of the second of the seco	Authorized officer

Form PCT/RO/134 (July 1992)

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

on page, line	
B. IDENTIFICATION OF DEPOSIT	Further deposits are identified on an additional sheet
Name of depositary institution	
AMERICAN TYPE CULTURE COLLECTION	
Address of depositary institution (including postal code	and country)
10801 University Blvd.	
Manassas, Virginia 20110-2209	
USA	
	·
Date of deposit	Accession Number
6 November 1996	ATCC98248
C. ADDITIONAL INDICATIONS (leave blank if not	applicable) This information is continued on an additional sheet
until the date on which the appli	f the grant of the European patent or
expert nominated by the person re	ly by the issue of such a sample to an equesting the sample. (Rule 28(4) EPC)
expert nominated by the person re	ly by the issue of such a sample to an
expert nominated by the person re	ly by the issue of such a sample to an equesting the sample. (Rule 28(4) EPC)
expert nominated by the person re	ly by the issue of such a sample to an equesting the sample. (Rule 28(4) EPC)
expert nominated by the person re	ly by the issue of such a sample to an equesting the sample. (Rule 28(4) EPC)
expert nominated by the person re	ly by the issue of such a sample to an equesting the sample. (Rule 28(4) EPC)
expert nominated by the person re	Ly by the issue of such a sample to an equesting the sample. (Rule 28(4) EPC) FIONS ARE MADE (if the indications are not for all designated States)
expert nominated by the person re D. DESIGNATED STATES FOR WHICH INDICAT E. SEPARATE FURNISHING OF INDICATIONS (I	Ly by the issue of such a sample to an equesting the sample. (Rule 28(4) EPC) FIONS ARE MADE (if the indications are not for all designated States) Reave blank if not applicable)
expert nominated by the person re D. DESIGNATED STATES FOR WHICH INDICAT E. SEPARATE FURNISHING OF INDICATIONS (The indications listed below will be submitted to the Inter	Ly by the issue of such a sample to an equesting the sample. (Rule 28(4) EPC) FIONS ARE MADE (if the indications are not for all designated States) Reave blank if not applicable)
expert nominated by the person re D. DESIGNATED STATES FOR WHICH INDICAT E. SEPARATE FURNISHING OF INDICATIONS (I	Ly by the issue of such a sample to an equesting the sample. (Rule 28(4) EPC) FIONS ARE MADE (if the indications are not for all designated States) Reave blank if not applicable)
expert nominated by the person re D. DESIGNATED STATES FOR WHICH INDICAT E. SEPARATE FURNISHING OF INDICATIONS (I	Ly by the issue of such a sample to an equesting the sample. (Rule 28(4) EPC) FIONS ARE MADE (if the indications are not for all designated States) Reave blank if not applicable)
expert nominated by the person re D. DESIGNATED STATES FOR WHICH INDICAT E. SEPARATE FURNISHING OF INDICATIONS (The indications listed below will be submitted to the Inter	Ly by the issue of such a sample to an equesting the sample. (Rule 28(4) EPC) FIONS ARE MADE (if the indications are not for all designated States) Reave blank if not applicable)
E. SEPARATE FURNISHING OF INDICATIONS (In indications listed below will be submitted to the Interview of Deposit') For receiving Office use only	Ly by the issue of such a sample to an equesting the sample. (Rule 28(4) EPC) FIONS ARE MADE (if the indications are not for all designated States) Reave blank if not applicable) mational Bureau later (specify the general nature of the indications e.g "Accessi
expert nominated by the person re D. DESIGNATED STATES FOR WHICH INDICAT E. SEPARATE FURNISHING OF INDICATIONS (In the indications listed below will be submitted to the International Companies)	Ly by the issue of such a sample to an equesting the sample. (Rule 28(4) EPC) FIONS ARE MADE (if the indications are not for all designated States) Reave blank if not applicable) mational Bureau later (specify the general nature of the indications e.g "Accessing the indications of the indicat
E. SEPARATE FURNISHING OF INDICATIONS (In the indications listed below will be submitted to the International of Deposit") For receiving Office use only This sheet was received with the international applications.	TIONS ARE MADE (if the indications are not for all designated States) Reave blank if not applicable) mational Bureau later (specify the general nature of the indications e.g "Accessing the indications of the indication
E. SEPARATE FURNISHING OF INDICATIONS (In indications listed below will be submitted to the Inter- Number of Deposit") For receiving Office use only	Ly by the issue of such a sample to an equesting the sample. (Rule 28(4) EPC) FIONS ARE MADE (if the indications are not for all designated States) Reave blank if not applicable) mational Bureau later (specify the general nature of the indications e.g "Accessing the indications of the indicat

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

on page 5 , line	
B. IDENTIFICATION OF DEPOSIT	Further deposits are identified on an additional sheet
Name of depositary institution	
AMERICAN TYPE CULTURE COLLECTION	
Address of depositary institution (including postal code	and country)
10801 University Blvd.	
Manassas, Virginia 20110-2209	
USA	
Date of deposit	Accession Number
25 November 1997	ATCC98597
C. ADDITIONAL INDICATIONS (leave blank if not	applicable) This information is continued on an additional sheet
the publication of the mention of until the date on which the appli or is deemed to be withdrawn, onl	rganism will be made available until f the grant of the European patent or ication has been refused or withdrawn
expert nominated by the person re	equesting the sample. (Rule 28(4) EPC)
	equesting the sample. (Rule 28(4) EPC) TIONS ARE MADE (if the indications are not for all designated States)
	equesting the sample. (Rule 28(4) EPC)
	equesting the sample. (Rule 28(4) EPC)
	equesting the sample. (Rule 28(4) EPC)
	equesting the sample. (Rule 28(4) EPC)
D. DESIGNATED STATES FOR WHICH INDICAT	equesting the sample. (Rule 28(4) EPC) TIONS ARE MADE (if the indications are not for all designated States)
D. DESIGNATED STATES FOR WHICH INDICATE E. SEPARATE FURNISHING OF INDICATIONS (TIONS ARE MADE (if the indications are not for all designated States)
D. DESIGNATED STATES FOR WHICH INDICATE E. SEPARATE FURNISHING OF INDICATIONS (The indications listed below will be submitted to the Inter	Equesting the sample. (Rule 28(4) EPC) TIONS ARE MADE (if the indications are not for all designated States) The sample of the indications are not for all designated States)
D. DESIGNATED STATES FOR WHICH INDICATE E. SEPARATE FURNISHING OF INDICATIONS (The indications listed below will be submitted to the Inter	TIONS ARE MADE (if the indications are not for all designated States)
D. DESIGNATED STATES FOR WHICH INDICATE E. SEPARATE FURNISHING OF INDICATIONS (The indications listed below will be submitted to the Inter	Equesting the sample. (Rule 28(4) EPC) TIONS ARE MADE (if the indications are not for all designated States) The sample of the indications are not for all designated States)
D. DESIGNATED STATES FOR WHICH INDICATE E. SEPARATE FURNISHING OF INDICATIONS (The indications listed below will be submitted to the Inter	Equesting the sample. (Rule 28(4) EPC) TIONS ARE MADE (if the indications are not for all designated States) The sample of the indications are not for all designated States)
D. DESIGNATED STATES FOR WHICH INDICATE E. SEPARATE FURNISHING OF INDICATIONS (A Che indications listed below will be submitted to the Inter- Number of Deposit")	requesting the sample. (Rule 28(4) EPC) TIONS ARE MADE (if the indications are not for all designated States) The sample of the indications are not for all designated States) The sample of the indications e.g., "Accessing the indications e.g.," "Accessing the indications e.g
D. DESIGNATED STATES FOR WHICH INDICATE E. SEPARATE FURNISHING OF INDICATIONS (The indications listed below will be submitted to the Inter Number of Deposit") For receiving Office use only	TIONS ARE MADE (if the indications are not for all designated States) Therefore blank if not applicable) The indication of the indications e.g "Accessional Bureau later (specify the general nature of the indications e.g "Accessional Bureau use only
D. DESIGNATED STATES FOR WHICH INDICATE E. SEPARATE FURNISHING OF INDICATIONS (A Charles) The indications listed below will be submitted to the Interview of Deposit")	TIONS ARE MADE (if the indications are not for all designated States) Therefore blank if not applicable) The indication of the indications are not for all designated States) The indication of the indication
E. SEPARATE FURNISHING OF INDICATIONS (The indications listed below will be submitted to the Inter Number of Deposit") For receiving Office use only This sheet was received with the international applic	TIONS ARE MADE (if the indications are not for all designated States) Therefore blank if not applicable) The indication and the indications e.g "Accession of the indications e.g" For International Bureau use only cation on:
D. DESIGNATED STATES FOR WHICH INDICATE E. SEPARATE FURNISHING OF INDICATIONS (The indications listed below will be submitted to the Inter Number of Deposit") For receiving Office use only	TIONS ARE MADE (if the indications are not for all designated States) Therefore blank if not applicable) The indication of the indications e.g "Accessional Bureau later (specify the general nature of the indications e.g "Accessional Bureau use only

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

B. IDENTIFICATION OF DEPOSIT	Further deposits are identified on an additional sheet
Name of depositary institution	
AMERICAN TYPE CULTURE COLLECTION	
Address of depositary institution (including postal code and	d country)
10801 University Blvd. ·	
Manassas, Virginia 20110-2209 USA	
OUA	
Date of deposit	Accession Number
25 November 1997	ATCC98598
C ADDITIONAL INDICATIONS (Lange Market)	
C. ADDITIONAL INDICATIONS (leave blank if not ap	pplicable) This information is continued on an additional sheet
the publication of the mention of	anism will be made available until the grant of the European patent or
until the date on which the application of until the date on which the application or is deemed to be withdrawn, only expert nominated by the person requirements.	the grant of the European patent or ation has been refused or withdrawn by the issue of such a sample to an uesting the sample. (Rule 28(4) EPC)
until the date on which the application of until the date on which the application or is deemed to be withdrawn, only expert nominated by the person requirements.	the grant of the European patent or ation has been refused or withdrawn by the issue of such a sample to an uesting the sample. (Rule 28(4) EPC)
until the date on which the application of until the date on which the application or is deemed to be withdrawn, only expert nominated by the person requirements.	the grant of the European patent or ation has been refused or withdrawn by the issue of such a sample to an uesting the sample. (Rule 28(4) EPC)
until the date on which the application of until the date on which the application or is deemed to be withdrawn, only expert nominated by the person requirements.	the grant of the European patent or ation has been refused or withdrawn by the issue of such a sample to an uesting the sample. (Rule 28(4) EPC)
until the date on which the application of until the date on which the application or is deemed to be withdrawn, only expert nominated by the person requirements.	the grant of the European patent or ation has been refused or withdrawn by the issue of such a sample to an uesting the sample. (Rule 28(4) EPC)
until the date on which the application of until the date on which the application or is deemed to be withdrawn, only expert nominated by the person requirements.	the grant of the European patent or ation has been refused or withdrawn by the issue of such a sample to an uesting the sample. (Rule 28(4) EPC)
the publication of the mention of until the date on which the application or is deemed to be withdrawn, only expert nominated by the person required. DESIGNATED STATES FOR WHICH INDICATION.	the grant of the European patent or ation has been refused or withdrawn by the issue of such a sample to an uesting the sample. (Rule 28(4) EPC) ONS ARE MADE (if the indications are not for all designated States)
the publication of the mention of until the date on which the application or is deemed to be withdrawn, only expert nominated by the person required by the indications listed below will be submitted to the International Control of t	the grant of the European patent or ation has been refused or withdrawn by the issue of such a sample to an uesting the sample. (Rule 28(4) EPC) ONS ARE MADE (if the indications are not for all designated States) we blank if not applicable)
the publication of the mention of until the date on which the application or is deemed to be withdrawn, only expert nominated by the person required. D. DESIGNATED STATES FOR WHICH INDICATION D. SEPARATE FURNISHING OF INDICATIONS (learning in the indications listed below will be submitted to the Internation	the grant of the European patent or ation has been refused or withdrawn by the issue of such a sample to an uesting the sample. (Rule 28(4) EPC) ONS ARE MADE (if the indications are not for all designated States) we blank if not applicable)
the publication of the mention of until the date on which the application or is deemed to be withdrawn, only expert nominated by the person required by the indications listed below will be submitted to the International Control of t	the grant of the European patent or ation has been refused or withdrawn by the issue of such a sample to an uesting the sample. (Rule 28(4) EPC) ONS ARE MADE (if the indications are not for all designated States) we blank if not applicable)
the publication of the mention of until the date on which the application or is deemed to be withdrawn, only expert nominated by the person required by the indications listed below will be submitted to the International Control of t	the grant of the European patent or ation has been refused or withdrawn by the issue of such a sample to an uesting the sample. (Rule 28(4) EPC) ONS ARE MADE (if the indications are not for all designated States) we blank if not applicable)
the publication of the mention of until the date on which the application or is deemed to be withdrawn, only expert nominated by the person required. D. DESIGNATED STATES FOR WHICH INDICATION D. SEPARATE FURNISHING OF INDICATIONS (learning in the indications listed below will be submitted to the Internation	the grant of the European patent or ation has been refused or withdrawn by the issue of such a sample to an uesting the sample. (Rule 28(4) EPC) ONS ARE MADE (if the indications are not for all designated States) we blank if not applicable)
the publication of the mention of until the date on which the application or is deemed to be withdrawn, only expert nominated by the person required. D. DESIGNATED STATES FOR WHICH INDICATION D. SEPARATE FURNISHING OF INDICATIONS (learning in the indications listed below will be submitted to the Internation	the grant of the European patent or ation has been refused or withdrawn by the issue of such a sample to an uesting the sample. (Rule 28(4) EPC) ONS ARE MADE (if the indications are not for all designated States) we blank if not applicable) tional Bureau later (specify the general nature of the indications e.g., "Accessional Bureau later (specify the general nature of the indications e.g., "Accessional Bureau later (specify the general nature of the indications e.g., "Accessional Bureau later (specify the general nature of the indications e.g., "Accessional Bureau later (specify the general nature of the indications e.g., "Accessional Bureau later (specify the general nature of the indications e.g., "Accessional Bureau later (specify the general nature of the indications e.g., "Accessional Bureau later (specify the general nature of the indications e.g., "Accessional Bureau later (specify the general nature of the indications e.g., "Accessional Bureau later (specify the general nature of the indications e.g., "Accessional Bureau later (specify the general nature of the indications e.g., "Accessional Bureau later (specify the general nature of the indications e.g., "Accessional Bureau later (specify the general nature of the indications e.g., "Accessional Bureau later (specify the general nature of the indications e.g., "Accessional Bureau later (specify the general nature of the indications e.g., "Accessional Bureau later (specify the general nature of the indications e.g., "Accessional Bureau later (specify the general nature of the indications e.g., "Accessional Bureau later (specify the general nature of the indications e.g., "Accessional Bureau later (specify the general nature of the indications e.g., "Accessional Bureau later (specify the general nature of the indications e.g., "Accessional Bureau later (specify the general nature of the indications e.g., "Accessional Bureau later (specify the general nature of the indications e.g., "Accessional Bureau later (specify the general nature of the indicatio
the publication of the mention of until the date on which the application or is deemed to be withdrawn, only expert nominated by the person requirement. D. DESIGNATED STATES FOR WHICH INDICATION. C. SEPARATE FURNISHING OF INDICATIONS (learning indications listed below will be submitted to the International Company of Deposit")	the grant of the European patent or ation has been refused or withdrawn by the issue of such a sample to an uesting the sample. (Rule 28(4) EPC) ONS ARE MADE (if the indications are not for all designated States) we blank if not applicable) tional Bureau later (specify the general nature of the indications e.g "Accessional Bureau use only
the publication of the mention of until the date on which the application or is deemed to be withdrawn, only expert nominated by the person requirement. D. DESIGNATED STATES FOR WHICH INDICATION. D. DESIGNATED STATES FOR WHICH INDICATION. The indications listed below will be submitted to the International Journal of Deposit") For receiving Office use only	the grant of the European patent or ation has been refused or withdrawn by the issue of such a sample to an uesting the sample. (Rule 28(4) EPC) ONS ARE MADE (if the indications are not for all designated States) we blank if not applicable) tional Bureau later (specify the general nature of the indications e.g "Accessed in the indications of the indications e.g."
the publication of the mention of until the date on which the application or is deemed to be withdrawn, only expert nominated by the person requirement. D. DESIGNATED STATES FOR WHICH INDICATION. D. DESIGNATED STATES FOR WHICH INDICATION. The indications listed below will be submitted to the International Journal of Deposit") For receiving Office use only	the grant of the European patent or ation has been refused or withdrawn by the issue of such a sample to an uesting the sample. (Rule 28(4) EPC) ONS ARE MADE (if the indications are not for all designated States) we blank if not applicable) tional Bureau later (specify the general nature of the indications e.g., "Accessed in the indications of the in

WHAT IS CLAIMED IS:

5

20

30

1. A method for the production of glycerol from a recombinant organism comprising:

- (i) transforming a suitable host cell with an expression cassette comprising either one or both of
- (a) a gene encoding a protein having glycerol-3-phosphate dehydrogenase activity, and
- (b) a gene encoding a protein having glycerol-3-phosphate phosphatase activity,
- 10 the suitable host cell having a disruption in either one or both of
 - (a) an endogenous gene encoding a polypeptide having glycerol kinase activity, and
 - (b) an endogenous gene encoding a polypeptide having glycerol dehydrogenase activity,
- wherein the disruption prevents the expression of active gene product;
 - (ii) culturing the transformed host cell of (i) in the presence of at least one carbon source selected from the group consisting of monosaccharides, oligosaccharides, polysaccharides, and single-carbon substrates, whereby glycerol is produced; and
 - (iii) optionally recovering the glycerol produced in (ii).
 - 2. The method of Claim 1 wherein the expression cassette comprises a gene encoding a glycerol-3-phosphate dehydrogenase enzyme.
 - 3. The method of Claim 1 wherein the expression cassette comprises a gene encoding a glycerol-3-phosphate phosphatase enzyme.
- 4. The method of Claim 1 wherein the expression cassette comprises genes encoding a glycerol-3-phosphate phosphate enzyme and a glycerol-3-phosphate dehydrogenase enzyme.
 - 5. The method of Claim 1 wherein the host cell contains a disruption in a gene encoding an endogenous glycerol kinase enzyme wherein the disruption prevents the expression of active gene product.
 - 6. The method of Claim 1 wherein the host cell contains a disruption in a gene encoding an endogenous glycerol dehydrogenase enzyme wherein the disruption prevents the expression of active gene product.
- 7. The method of Claim 1 wherein the host cell contains a) a disruption in a gene encoding an endogenous glycerol kinase enzyme and b) a disruption in a gene encoding an endogenous glycerol dehydrogenase enzyme, wherein the disruptions in the respective genes prevent the expression of active gene product from either gene.

8. The method of Claim 1 wherein the suitable host cell is selected from the group consisting of bacteria, yeast, and filamentous fungi.

- 9. The method of Claim 8 wherein the suitable host cell is selected from the group consisting of Citrobacter, Enterobacter, Clostridium, Klebsiella, Aerobacter, Lactobacillus, Aspergillus, Saccharomyces, Schizosaccharomyces, Zygosaccharomyces, Pichia, Kluyveromyces, Candida, Hansenula, Debaryomyces, Mucor, Torulopsis, Methylobacter, Escherichia, Salmonella, Bacillus, Streptomyces, and Pseudomonas.
- 10. The method of Claim 9 wherein the suitable host cell is E. coli or Saccharomyces sp.
 - 11. The method of Claim 1 wherein the carbon source is glucose.
 - 12. The method of Claim 1 wherein the protein having glycerol-3-phosphate dehydrogenase activity corresponds to amino acid sequences selected from the group consisting of SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9,
- SEQ ID NO:10, SEQ ID NO:11, and SEQ ID NO:12 and wherein the amino acid sequences encompasses amino acid substitutions, deletions or insertions that do not alter the functional properties of the enzyme.
 - 13. The method of Claim 1 wherein the protein having glycerol-3-phosphatase activity corresponds to the amino acid sequences selected from the group consisting of SEQ ID NO:13 and SEQ ID NO:14, and wherein the amino acid sequences may encompass amino acid substitutions, deletions or additions that do not alter the function of the enzyme.
 - 14. A transformed host cell comprising:

20

- (a) a gene encoding a protein having a glycerol-3-phosphate dehydrogenase activity;
 - (b) a gene encoding a protein having glycerol-3-phosphate phosphatase activity;
 - (c) a disruption in a gene encoding an endogenous glycerol kinase and;
- (d) a disruption a gene encoding an endogenous glycerol dehydrogenase;
 wherein the disruptions in the genes of (c) and (d) prevent the expression of active gene product, and wherein the host cell converts at least one carbon source selected from the group consisting of monosaccharides, oligosaccharides, polysaccharides, and single-carbon substrates to glycerol.
 - 15. A transformed host cell comprising:
 - (a) a gene encoding a protein having a glycerol-3-phosphate dehydrogenase activity;

(b) a gene encoding a protein having glycerol-3-phosphate phosphatase activity; and

- (c) a disruption in a gene encoding an endogenous glycerol dehydrogenase;
- wherein the disruption in the gene of (c) prevents the expression of active gene product, and wherein the host cell converts at least one carbon source selected from the group consisting of monosaccharides, oligosaccharides, polysaccharides, and single-carbon substrates to glycerol.
 - 16. A transformed host cell comprising:

20

30

35

- 10 (a) a gene encoding a protein having a glycerol-3-phosphate dehydrogenase activity;
 - (b) a gene encoding a protein having glycerol-3-phosphate phosphatase activity; and
- (c) a disruption in a gene encoding an endogenous glycerol kinase,

wherein the disruption in the gene of (c) prevents the expression of active gene product, and wherein the host cell converts at least one carbon source selected from the group consisting of monosaccharides, oligosaccharides, polysaccharides, and single-carbon substrates to glycerol.

- 17. A method for the production of 1,3-propanediol from a recombinant organism comprising:
- (i) transforming a suitable host cell with an expression cassette comprising either one or both of
- (a) a gene encoding a protein having glycerol-3-phosphate dehydrogenase activity, and
 - (b) a gene encoding a protein having glycerol-3-phosphate phosphatase activity,

the suitable host cell having at least one gene encoding a protein having a dehydratase activity and having a disruption in either one or both of:

- (a) an endogenous gene encoding a polypeptide having glycerol kinase activity, and
- (b) an endogenous gene encoding a polypeptide having glycerol dehydrogenase activity,
- wherein the disruption in the genes of (a) or (b) prevents the expression of active gene product;
 - (ii) culturing the transformed host cell of (i) in the presence of at least one carbon source selected from the group consisting of monosaccharides, oligosaccharides, polysaccharides, and single-carbon substrates whereby 1,3-propanediol is produced; and

- (iii) recovering the 1,3-propanediol produced in (ii).
- 18. The method of Claim 17 wherein the protein having a dehydratase activity is selected from the group consisting of a glycerol dehydratase enzyme and a diol dehydratase enzyme.
- 19. The method of Claim 18 wherein the glycerol dehydratase enzyme is encoded by a gene, the gene isolated from a microorganism, the microorganism selected from the group consisting of *Klebsiella*, *Lactobacillus*, *Enterobacter*, *Citrobacter*, *Pelobacter*, *Ilyobacter*, and *Clostridium*.

5

20. The method of Claim 18 wherein the diol dehydratase enzyme is encoded by a gene, the gene isolated from a microorganism, the microorganism selected from the group consisting of *Klebsiella* and *Salmonella*.

SEQUENCE LISTING

- (1) GENERAL INFORMATION:
 - (i) APPLICANT:
 - (A) NAME: E. I. DU PONT DE NEMOURS AND COMPANY
 - (B) STREET: 1007 MARKET STREET
 - (C) CITY: WILMINGTON
 - (D) STATE: DELAWARE
 - (E) COUNTRY: U.S.A.
 - (F) ZIP: 19898
 - (G) TELEPHONE: 302-892-8112
 - (H) TELEFAX: 302-773-0164
 - (I) TELEX: 6717325
 - (ii) TITLE OF INVENTION: METHOD FOR THE PRODUCTION OF GLYCEROL BY RECOMBINANT ORGANISMS
 - (iii) NUMBER OF SEQUENCES: 43
 - (iv) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: DISKETTE, 3.5 INCH
 - (B) COMPUTER: IBM PC COMPATIBLE
 - (C) OPERATING SYSTEM: MICROSOFT WINDOWS 95
 - (D) SOFTWARE: MICROSOFT WORD VERSION 7.0A
 - (v) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER:
 - (B) FILING DATE:
 - (C) CLASSIFICATION:
 - (vi) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: 08/982,783
 - (B) FILING DATE: DECEMBER 2, 1997
 - (C) CLASSIFICATION:
 - (vii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: FLOYD, LINDA AXAMETHY
 - (B) REGISTRATION NUMBER: 33,692
 - (C) REFERENCE/DOCKET NUMBER: CR-9981-C

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 1380 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

CTTTAATTTT	CTTTTATCTT	ACTCTCCTAC	ATAAGACATC	AAGAAACAAT	TGTATATTGT	60
ACACCCCCC	CCTCCACAAA	CACAAATATT	GATAATATAA	AGATGTCTGC	TGCTGCTGAT	120
AGATTAAACT	TAACTTCCGG	CCACTTGAAT	GCTGGTAGAA	AGAGAAGTTC	CTCTTCTGTT	180
TCTTTGAAGG	CTGCCGAAAA	GCCTTTCAAG	GTTACTGTGA	TTGGATCTGG	TAACTGGGGT	240
ACTACTATTG	CCAAGGTGGT	TGCCGAAAAT	TGTAAGGGAT	ACCCAGAAGT	TTTCGCTCCA	300
ATAGTACAAA	TGTGGGTGTT	CGAAGAAGAG	ATCAATGGTG	AAAAATTGAC	TGAAATCATA	360
AATACTAGAC	ATCAAAACGT	GAAATACTTG	CCTGGCATCA	CTCTACCCGA	CAATTTGGTT	420
GCTAATCCAG	ACTTGATTGA	TTCAGTCAAG	GATGTCGACA	TCATCGTTTT	CAACATTCCA	480
CATCAATTTT	TGCCCCGTAT	CTGTAGCCAA	TTGAAAGGTC	ATGTTGATTC	ACACGTCAGA	540
GCTATCTCCT	GTCTAAAGGG	TTTTGAAGTT	GGTGCTAAAG	GTGTCCAATT	GCTATCCTCT	600
TACATCACTG	AGGAACTAGG	TATTCAATGT	GGTGCTCTAT	CTGGTGCTAA	CATTGCCACC	660
GAAGTCGCTC	AAGAACACTG	GTCTGAAACA	ACAGTTGCTT	ACCACATTCC	AAAGGATTTC	720
AGAGGCGAGG	GCAAGGACGT	CGACCATAAG	GTTCTAAAGG	CCTTGTTCCA	CAGACCTTAC	780
TTCCACGTTA	GTGTCATCGA	AGATGTTGCT	GGTATCTCCA	TCTGTGGTGC	TTTGAAGAAC	840
GTTGTTGCCT	TAGGTTGTGG	TTTCGTCGAA	GGTCTAGGCT	GGGGTAACAA	CGCTTCTGCT	900
GCCATCCAAA	GAGTCGGTTT	GGGTGAGATC	ATCAGATTCG	GTCAAATGTT	TTTCCCAGAA	960
TCTAGAGAAG	AAACATACTA	CCAAGAGTCT	GCTGGTGTTG	CTGATTTGAT	CACCACCTGC	1020
GCTGGTGGTA	GAAACGTCAA	GGTTGCTAGG	CTAATGGCTA	CTTCTGGTAA	GGACGCCTGG	1080
GAATGTGAAA	AGGAGTTGTT	GAATGGCCAA	TCCGCTCAAG	GTTTAATTAC	CTGCAAAGAA	1140
GTTCACGAAT	GGTTGGAAAC	ATGTGGCTCT	GTCGAAGACT	TCCCATTATT	TGAAGCCGTA	1200
TACCAAATCG	TTTACAACAA	CTACCCAATG	AAGAACCTGC	CGGACATGAT	TGAAGAATTA	1260
GATCTACATG	AAGATTAGAT	TTATTGGAGA	AAGATAACAT	ATCATACTTC	CCCCACTTTT	1320
TTCGAGGCTC	TTCTATATCA	TATTCATAAA	TTAGCATTAT	GTCATTTCTC	ATAACTACTT	1380

PCT/US98/25551 WO 99/28480

(2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 2946 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single

 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

GAATTCGAGC	CTGAAGTGCT	GATTACCTTC	AGGTAGACTT	CATCTTGACC	CATCAACCCC	60
						60
AGCGTCAATC	CTGCAAATAC	ACCACCCAGC	AGCACTAGGA	TGATAGAGAT	AATATAGTAC	120
GTGGTAACGC	TTGCCTCATC	ACCTACGCTA	TGGCCGGAAT	CGGCAACATC	CCTAGAATTG	180
AGTACGTGTG	ATCCGGATAA	CAACGGCAGT	GAATATATCT	TCGGTATCGT	AAAGATGTGA	240
TATAAGATGA	TGTATACCCA	ATGAGGAGCG	CCTGATCGTG	ACCTAGACCT	TAGTGGCAAA	300
AACGACATAT	CTATTATAGT	GGGGAGAGTT	TCGTGCAAAT	AACAGACGCA	GCAGCAAGTA	360
ACTGTGACGA	TATCAACTCT	TTTTTTATTA	TGTAATAAGC	AAACAAGCAC	GAATGGGGAA	420
AGCCTATGTG	CAATCACCAA	GGTCGTCCCT	TTTTTCCCAT	TTGCTAATTT	AGAATTTAAA	480
GAAACCAAAA	GAATGAAGAA	AGAAAACAAA	TACTAGCCCT	AACCCTGACT	TCGTTTCTAT	540
GATAATACCC	TGCTTTAATG	AACGGTATGC	CCTAGGGTAT	ATCTCACTCT	GTACGTTACA	600
AACTCCGGTT	ATTTTATCGG	AACATĈCGAG	CACCCGCGCC	TTCCTCAACC	CAGGCACCGC	660
CCCAGGTAAC	CGTGCGCGAT	GAGCTAATCC	TGAGCCATCA	CCCACCCCAC	CCGTTGATGA	720
CAGCAATTCG	GGAGGGCGAA	AATAAAACTG	GAGCAAGGAA	TTACCATCAC	CGTCACCATC	780
ACCATCATAT	CGCCTTAGCC	TCTAGCCATA	GCCATCATGC	AAGCGTGTAT	CTTCTAAGAT	840
TCAGTCATCA	TCATTACCGA	GTTTGTTTTC	CTTCACATGA	TGAAGAAGGT	TTGAGTATGC	900
TCGAAACAAT	AAGACGACGA	TGGCTCTGCC	ATTGGTTATA	TTACGCTTTT	GCGGCGAGGT	960
GCCGATGGGT	TGCTGAGGGG	AAGAGTGTTT	AGCTTACGGA	CCTATTGCCA	TTGTTATTCC	1020
GATTAATCTA	TTGTTCAGCA	GCTCTTCTCT	ACCCTGTCAT	TCTAGTATTT	TTTTTTTTT	1080
TTTTTGGTTT	TACTTTTTT	TCTTCTTGCC	TTTTTTTTTT	GTTACTTTTT	TTCTAGTTTT	1140
TTTTCCTTCC	ACTAAGCTTT	TTCCTTGATT	TATCCTTGGG	TTCTTCTTTC	TACTCCTTTA	1200
GATTTTTTT	TTATATATTA	ATTTTTAAGT	TTATGTATTT	TGGTAGATTC	AATTCTCTTT	1260
CCCTTTCCTT	TTCCTTCGCT	CCCCTTCCTT	ATCAATGCTT	GCTGTCAGAA	GATTAACAAG	1320
ATACACATTC	CTTAAGCGAA	CGCATCCGGT	GTTATATACT	CGTCGTGCAT	ATAAAATTTT	1380

GCCTTCAAGA	TCTACTTTCC	TAAGAAGATC	ATTATTACAA	ACACAACTGC	ACTCAAAGAT	1440
GACTGCTCAT	ACTAATATCA	AACAGCACAA	ACACTGTCAT	GAGGACCATC	CTATCAGAAG	1500
ATCGGACTCT	GCCGTGTCAA	TTGTACATTT	GAAACGTGCG	CCCTTCAAGG	TTACAGTGAT	1560
TGGTTCTGGT	AACTGGGGGA	CCACCATCGC	CAAAGTCATT	GCGGAAAACA	CAGAATTGCA	1620
TTCCCATATC	TTCGAGCCAG	AGGTGAGAAT	GTGGGTTTTT	GATGAAAAGA	TCGGCGACGA	1680
AAATCTGACG	GATATCATAA	ÁTACAAGACA	CCAGAACGTT	AAATATCTAC	CCAATATTGA	1740
CCTGCCCCAT	AATCTAGTGG	CCGATCCTGA	TCTTTTACAC	TCCATCAAGG	GTGCTGACAT	1800
CCTTGTTTTC	AACATCCCTC	ATCAATTTTT	ACCAAACATA	GTCAAACAAT	TGCAAGGCCA	1860
CGTGGCCCCT	CATGTAAGGG	CCATCTCGTG	TCTAAAAGGG	TTCGAGTTGG	GCTCCAAGGG	1920
TGTGCAATTG	CTATCCTCCT	ATGTTACTGA	TGAGTTAGGA	ATCCAATGTG	GCGCACTATC	1980
TGGTGCAAAC	TTGGCACCGG	AAGTGGCCAA	GGAGCATTGG	TCCGAAACCA	CCGTGGCTTA	2040
CCAACTACCA	AAGGATTATC	AAGGTGATGG	CAAGGATGTA	GATCATAAGA	TTTTGAAATT	2100
GCTGTTCCAC	AGACCTTACT	TCCACGTCAA	TGTCATCGAT	GATGTTGCTG	GTATATCCAT	2160
TGCCGGTGCC	TTGAAGAACG	TCGTGGCACT	TGCATGTGGT	TTCGTAGAAG	GTATGGGATG	2220
GGGTAACAAT	GCCTCCGCAG	CCATTCAAAG	GCTGGGTTTA	GGTGAAATTA	TCAAGTTCGG	2280
TAGAATGTTT	TTCCCAGAAT	CCAAAGTCGA	GACCTACTAT	CAAGAATCCG	CTGGTGTTGC	2340
AGATCTGATC	ACCACCTGCT	CAGGCGGTAG	AAACGTCAAG	GTTGCCACAT	ACATGGCCAA	2400
GACCGGTAAG	TCAGCCTTGG	AAGCAGAAAA	GGAATTGCTT	AACGGTCAAT	CCGCCCAAGG	2460
GATAATCACA	TGCAGAGAAG	TTCACGAGTG	GCTACAAACA	TGTGAGTTGA	CCCAAGAATT	2520
CCCAATTATT	CGAGGCAGTC	TACCAGATAG	TCTACAACAA	CGTCCGCATG	GAAGACCTAC	2580
CGGAGATGAT	TGAAGAGCTA	GACATCGATG	ACGAATAGAC	ACTCTCCCC	CCCCTCCCC	2640
TCTGATCTTT	CCTGTTGCCT	CTTTTTCCCC	CAACCAATTT	ATCATTATAC	ACAAGTTCTA	2700
CAACTACTAC	TAGTAACATT	ACTACAGTTA	TTATAATTTT	CTATTCTCTT	TTTCTTTAAG	2760
AATCTATCAT	TAACGTTAAT	TTCTATATAT	ACATAACTAC	CATTATACAC	GCTATTATCG	2820
TTTACATATC	ACATCACCGT	TAATGAAAGA	TACGACACCC	TGTACACTAA	CACAATTAAA	2880
TAATCGCCAT	AACCTTTTCT	GTTATCTATA	GCCCTTAAAG	CTGTTTCTTC	GAGCTTTTCA	2940
CTGCAG						2946

PCT/US98/25551 WO 99/28480

(2) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 3178 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

CTGCAGAACT TCGTCTG	CTC TGTGCCCATC	CTCGCGGTTA	GAAAGAAGCT	GAATTGTTTC	60
ATGCGCAAGG GCATCAG	CGA GTGACCAATA	ATCACTGCAC	TAATTCCTTT	TTAGCAACAC	120
ATACTTATAT ACAGCAC	CAG ACCTTATGTC	TTTTCTCTGC	TCCGATACGT	TATCCCACCC	180
AACTTTTATT TCAGTTT	TGG CAGGGGAAAT	TTCACAACCC	CGCACGCTAA	AAATCGTATT	240
TAAACTTAAA AGAGAAC	AGC CACAAATAGG	GAACTTTGGT	CTAAACGAAG	GACTCTCCCT	300
CCCTTATCTT GACCGTG	CTA TTGCCATCAC	TGCTACAAGA	CTAAATACGT	ACTAATATAT	360
GTTTTCGGTA ACGAGAA	GAA GAGCTGCCGG	TGCAGCTGCT	GCCATGGCCA	CAGCCACGGG	420
GACGCTGTAC TGGATGA	CTA GCCAAGGTGA	TAGGCCGTTA	GTGCACAATG	ACCCGAGCTA	480
CATGGTGCAA TTCCCCA	CCG CCGCTCCACC	GGCAGGTCTC	TAGACGAGAC	CTGCTGGACC	540
GTCTGGACAA GACGCAT	CAA TTCGACGTGT	TGATCATCGG	TGGCGGGGCC	ACGGGGACAG	600
GATGTGCCCT AGATGCT	GCG ACCAGGGGAC	TCAATGTGGC	CCTTGTTGAA	AAGGGGGATT	660
TTGCCTCGGG AACGTCG	TCC AAATCTACCA	AGATGATTCA	CGGTGGGGTG	CGGTACTTAG	720
AGAAGGCCTT CTGGGAG	TTC TCCAAGGCAC	AACTGGATCT	GGTCATCGAG	GCACTCAACG	780
AGCGTAAACA TCTTATC	AAC ACTGCCCCTC	ACCTGTGCAC	GGTGCTACCA	ATTCTGATCC	840
CCATCTACAG CACCTGG	CAG GTCCCGTACA	TCTATATGGG	CTGTAAATTC	TACGATTTCT	900
TTGGCGGTTC CCAAAAC	TTG AAAAAATCAT	ACCTACTGTC	CAAATCCGCC	ACCGTGGAGA	960
AGGCTCCCAT GCTTACC	ACA GACAATTTAA	AGGCCTCGCT	TGTGTACCAT	GATGGGTCCT	1020
TTAACGACTC GCGTTTG	AAC GCCACTTTAG	CCATCACGGG	TGTGGAGAAC	GGCGCTACCG	1080
TCTTGATCTA TGTCGAG	GTA CAAAAATTGA	TCAAAGACCC	AACTTCTGGT	AAGGTTATCG	1140
GTGCCGAGGC CCGGGAC	GTT GAGACTAATG	AGCTTGTCAG	AATCAACGCT	AAATGTGTGG	1200
TCAATGCCAC GGGCCCA	TAC AGTGACGCCA	TTTTGCAAAT	GGACCGCAAC	CCATCCGGTC	1260
TGCCGGACTC CCCGCTA	AAC GACAACTCCA	AGATCAAGTC	GACTTTCAAT	CAAATCTCCG	1320
TCATGGACCC GAAAATG	GTC ATCCCATCTA	TTGGCGTTCA	CATCGTATTG	CCCTCTTTTT	1380

ACTCCCCGAA	GGATATGGGT	TTGTTGGACG	TCAGAACCTC	TGATGGCAGA	GTGATGTTCT	1440
TTTTACCTTG	GCAGGGCAAA	GTCCTTGCCG	GCACCACAGA	CATCCCACTA	AAGCAAGTCC	1500
CAGAAAACCC	TATGCCTACA	GAGGCTGATA	TTCAAGATAT	CTTGAAAGAA	CTACAGCACT	1560
ATATCGAATT	CCCCGTGAAA	AGAGAAGACG	TGCTAAGTGC	ATGGGCTGGT	GTCAGACCTT	1620
TGGTCAGAGA	TCCACGTACA	ATCCCCGCAG	ACGGGAAGAA	GGGCTCTGCC	ACTCAGGGCG	1680
TGGTAAGATC	CCACTTCTTG	TTCACTTCGG	ATAATGGCCT	AATTACTATT	GCAGGTGGTA	1740
AATGGACTAC	TTACAGACAA	ATGGCTGAGG	AAACAGTCGA	CAAAGTTGTC	GAAGTTGGCG	1800
GATTCCACAA	CCTGAAACCT	TGTCACACAA	GAGATATTAA	GCTTGCTGGT	GCAGAAGAAT	1860
GGACGCAAAA	CTATGTGGCT	TTATTGGCTC	AAAACTACCA	TTTATCATCA	AAAATGTCCA	1920
ACTACTTGGT	TCAAAACTAC	GGAACCCGTT	CCTCTATCAT	TTGCGAATTT	TTCAAAGAAT	1980
CCATGGAAAA	TAAACTGCCT	TTGTCCTTAG	CCGACAAGGA	AAATAACGTA	ATCTACTCTA	2040
GCGAGGAGAA	CAACTTGGTC	AATTTTGATA	CTTTCAGATA	TCCATTCACA	ATCGGTGAGT	2100
TAAAGTATTC	CATGCAGTAC	GAATATTGTA	GAACTCCCTT	GGACTTCCTT	TTAAGAAGAA	2160
CAAGATTCGC	CTTCTTGGAC	GCCAAGGAAG	CTTTGAATGC	CGTGCATGCC	ACCGTCAAAG	2220
TTATGGGTGA	TGAGTTCAAT	TGGTCGGAGA	AAAAGAGGCA	GTGGGAACTT	GAAAAAACTG	2280
TGAACTTCAT	CCAAGGACGT	TTCGGTGTCT	AAATCGATCA	TGATAGTTAA	GGGTGACAAA	2340
GATAACATTC	ACAAGAGTAA	TAATAATGGT	AATGATGATA	АТААТААТАА	TGATAGTAAT	2400
AACAATAATA	ATAATGGTGG	TAATGGCAAT	GAAATCGCTA	TTATTACCTA	TTTTCCTTAA	2460
TGGAAGAGTT	AAAGTAAACT	ААААААСТА	СААААТАТА	TGAAGAAAAA	AAAAAAAAGA	2520
GGTAATAGAC	TCTACTACTA	CAATTGATCT	TCAAATTATG	ACCTTCCTAG	TGTTTATATT	2580
CTATTTCCAA	TACATAATAT	AATCTATATA	ATCATTGCTG	GTAGACTTCC	GTTTTAATAT	2640
CGTTTTAATT	ATCCCCTTTA	TCTCTAGTCT	AGTTTTATCA	TAAAATATAG	AAACACTAAA	2700
TAATATTCTT	CAAACGGTCC	TGGTGCATAC	GCAATACATA	TTTATGGTGC	АААААААА	2760
ATGGAAAATT	TTGCTAGTCA	TAAACCCTTT	САТААААСАА	TACGTAGACA	TCGCTACTTG	2820
AAATTTTCAA	GTTTTTATCA	GATCCATGTT	TCCTATCTGC	CTTGACAACC	TCATCGTCGA	2880
AATAGTACCA	TTTAGAACGC	CCAATATTCA	CATTGTGTTC	AAGGTCTTTA	TTCACCAGTG	2940
ACGTGTAATG	GCCATGATTA	ATGTGCCTGT	ATGGTTAACC	ACTCCAAATA	GCTTATATTT	3000
CATAGTGTCA	TTGTTTTTCA	ATATAATGTT	TAGTATCAAT	GGATATGTTA	CGACGGTGTT	3060
ATTTTTCTTG	GTCAAATCGT	AATAAAATCT	CGATAAATGG	ATGACTAAGA	TTTTTGGTAA	3120

AGTTACAAAA TTTATCGTTT TCACTGTTGT CAATTTTTTG TTCTTGTAAT CACTCGAG 3178

- (2) INFORMATION FOR SEQ ID NO:4:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 816 base pairs

 - (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: DNA (genomic)
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

ATGAAACGTT TCAATGTTTT AAAATATATC AGAACAACAA AAGCAAATAT ACAAACCATC 60 GCAATGCCTT TGACCACAAA ACCTTTATCT TTGAAAATCA ACGCCGCTCT ATTCGATGTT 120 GACGGTACCA TCATCATCTC TCAACCAGCC ATTGCTGCTT TCTGGAGAGA TTTCGGTAAA 180 GACAAGCCTT ACTTCGATGC CGAACACGTT ATTCACATCT CTCACGGTTG GAGAACTTAC 240 GATGCCATTG CCAAGTTCGC TCCAGACTTT GCTGATGAAG AATACGTTAA CAAGCTAGAA 300 GGTGAAATCC CAGAAAAGTA CGGTGAACAC TCCATCGAAG TTCCAGGTGC TGTCAAGTTG 360 TGTAATGCTT TGAACGCCTT GCCAAAGGAA AAATGGGCTG TCGCCACCTC TGGTACCCGT 420 GACATGGCCA AGAAATGGTT CGACATTTTG AAGATCAAGA GACCAGAATA CTTCATCACC 480 GCCAATGATG TCAAGCAAGG TAAGCCTCAC CCAGAACCAT ACTTAAAGGG TAGAAACGGT 540 TTGGGTTTCC CAATTAATGA ACAAGACCCA TCCAAATCTA AGGTTGTTGT CTTTGAAGAC 600 GCACCAGCTG GTATTGCTGC TGGTAAGGCT GCTGGCTGTA AAATCGTTGG TATTGCTACC 660 ACTITCGATT TGGACTICTT GAAGGAAAAG GGTTGTGACA TCATTGTCAA GAACCACGAA 720 TCTATCAGAG TCGGTGAATA CAACGCTGAA ACCGATGAAG TCGAATTGAT CTTTGATGAC 780 TACTTATACG CTAAGGATGA CTTGTTGAAA TGGTAA 816

- INFORMATION FOR SEO ID NO:5: (2)
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 753 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: DNA (genomic)
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

ATGGGATTGA CTACTAAACC TCTATCTTTG AAAGTTAACG CCGCTTTGTT CGACGTCGAC 60 GGTACCATTA TCATCTCCA ACCAGCCATT GCTGCATTCT GGAGGGATTT CGGTAAGGAC 120

AAACCTTATT	TCGATGCTGA	ACACGTTATC	CAAGTCTCGC	ATGGTTGGAG	AACGTTTGAT	180
GCCATTGCTA	AGTTCGCTCC	AGACTTTGCC	AATGAAGAGT	ATGTTAACAA	ATTAGAAGCT	240
GAAATTCCGG	TCAAGTACGG	TGAAAAATCC	ATTGAAGTCC	CAGGTGCAGT	TAAGCTGTGC	300
AACGCTTTGA	ACGCTCTACC	AAAAGAGAAA	TGGGCTGTGG	CAACTTCCGG	TACCCGTGAT	360
ATGGCACAAA	AATGGTTCGA	GCATCTGGGA	ATCAGGAGAC	CAAAGTACTT	CATTACCGCT	420
AATGATGTCA	AACAGGGTAA	GCCTCATCCA	GAACCATATC	TGAAGGGCAG	GAATGGCTTA	480
GGATATCCGA	TCAATGAGCA	AGACCCTTCC	AAATCTAAGG	TAGTAGTATT	TGAAGACGCT	540
CCAGCAGGTA	TTGCCGCCGG	AAAAGCCGCC	GGTTGTAAGA	TCATTGGTAT	TGCCACTACT	600
TTCGACTTGG	ACTTCCTAAA	GGAAAAAGGC	TGTGACATCA	TTGTCAAAAA	CCACGAATCC	660
ATCAGAGTTG	GCGGCTACAA	TGCCGAAACA	GACGAAGTTG	AATTCATTTT	TGACGACTAC	720
TTATATGCTA	AGGACGATCT	GTTGAAATGG	TAA			753

(2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 2520 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

TGTATTGGCC ACGATAACCA CCCTTTGTAT ACTGTTTTTG TTTTTCACAT GGTAAATAAC 60 GACTTTTATT AAACAACGTA TGTAAAAACA TAACAAGAAT CTACCCATAC AGGCCATTTC 120 GTAATTCTTC TCTTCTAATT GGAGTAAAAC CATCAATTAA AGGGTGTGGA GTAGCATAGT 180 GAGGGGCTGA CTGCATTGAC AAAAAAATTG AAAAAAAAA AGGAAAAGGA AAGGAAAAAA 240 AGACAGCCAA GACTTTTAGA ACGGATAAGG TGTAATAAAA TGTGGGGGGA TGCCTGTTCT 300 CGAACCATAT AAAATATACC ATGTGGTTTG AGTTGTGGCC GGAACTATAC AAATAGTTAT 360 ATGTTTCCCT CTCTCTCCG ACTTGTAGTA TTCTCCAAAC GTTACATATT CCGATCAAGC 420 CAGCGCCTTT ACACTAGTTT AAAACAAGAA CAGAGCCGTA TGTCCAAAAT AATGGAAGAT 480 TTACGAAGTG ACTACGTCCC GCTTATCGCC AGTATTGATG TAGGAACGAC CTCATCCAGA 540 TGCATTCTGT TCAACAGATG GGGCCAGGAC GTTTCAAAAC ACCAAATTGA ATATTCAACT 600 TCAGCATCGA AGGGCAAGAT TGGGGTGTCT GGCCTAAGGA GACCCTCTAC AGCCCCAGCT 660 CGTGAAACAC CAAACGCCGG TGACATCAAA ACCAGCGGAA AGCCCATCTT TTCTGCAGAA

GGCTATGCCA	TTCAAGAAAC	CAAATTCCTA	AAAATCGAGG	AATTGGACTT	GGACTTCCAT	780
AACGAACCCA	CGTTGAAGTT	CCCCAAACCG	GGTTGGGTTG	AGTGCCATCC	GCAGAAATTA	840
CTGGTGAACG	TCGTCCAATG	CCTTGCCTCA	AGTTTGCTCT	CTCTGCAGAC	TATCAACAGC	900
GAACGTGTAG	CAAACGGTCT	CCCACCTTAC	AAGGTAATAT	GCATGGGTAT	AGCAAACATG	960
AGAGAAACCA	CAATTCTGTG	GTCCCGCCGC	ACAGGAAAAC	CAATTGTTAA	CTACGGTATT	1020
GTTTGGAACG	ACACCAGAAC	GATCAAAATC	GTTAGAGACA	AATGGCAAAA	CACTAGCGTC	1080
GATAGGCAAC	TGCAGCTTAG	ACAGAAGACT	GGATTGCCAT	TGCTCTCCAC	GTATTTCTCC	1140
TGTTCCAAGC	TGCGCTGGTT	CCTCGACAAT	GAGCCTCTGT	GTACCAAGGC	GTATGAGGAG	1200
AACGACCTGA	TGTTCGGCAC	TGTGGACACA	TGGCTGATTT	ACCAATTAAC	TAAACAAAAG	1260
GCGTTCGTTT	CTGACGTAAC	CAACGCTTCC	AGAACTGGAT	TTATGAACCT	CTCCACTTTA	1320
AAGTACGACA	ACGAGTTGCT	GGAATTTTGG	GGTATTGACA	AGAACCTGAT	TCACATGCCC	1380
GAAATTGTGT	CCTCATCTCA	ATACTACGGT	GACTTTGGCA	TTCCTGATTG	GATAATGGAA	1440
AAGCTACACG	ATTCGCCAAA	AACAGTACTG	CGAGATCTAG	TCAAGAGAAA	CCTGCCCATA	1500
CAGGGCTGTC	TGGGCGACCA	AAGCGCATCC	ATGGTGGGGC	AACTCGCTTA	CAAACCCGGT	1560
GCTGCAAAAT	GTACTTATGG	TACCGGTTGC	TTTTTACTGT	ACAATACGGG	GACCAAAAAA	1620
TTGATCTCCC	AACATGGCGC	ACTGACGACT	CTAGCATTTT	GGTTCCCACA	TTTGCAAGAG	1680
TACGGTGGCC	AAAAACCAGA	ATTGAGCAAG	CCACATTTTG	CATTAGAGGG	TTCCGTCGCT	1740
GTGGCTGGTG	CTGTGGTCCA	ATGGCTACGT	GATAATTTAC	GATTGATCGA	TAAATCAGAG	1800
GATGTCGGAC	CGATTGCATC	TACGGTTCCT	GATTCTGGTG	GCGTAGTTTT	CGTCCCCGCA	1860
TTTAGTGGCC	TATTCGCTCC	CTATTGGGAC	CCAGATGCCA	GAGCCACCAT	AATGGGGATG	1920
TCTCAATTCA	CTACTGCCTC	CCACATCGCC	AGAGCTGCCG	TGGAAGGTGT	TTGCTTTCAA	1980
GCCAGGGCTA	TCTTGAAGGC	AATGAGTTCT	GACGCGTTTG	GTGAAGGTTC	CAAAGACAGG	2040
GACTTTTTAG	AGGAAATTTC	CGACGTCACA	TATGAAAAGT	CGCCCCTGTC	GGTTCTGGCA	2100
GTGGATGGCG	GGATGTCGAG	GTCTAATGAA	GTCATGCAAA	TTCAAGCCGA	TATCCTAGGT	2160
CCCTGTGTCA	AAGTCAGAAG	GTCTCCGACA	GCGGAATGTA	CCGCATTGGG	GGCAGCCATT	2220
GCAGCCAATA	TGGCTTTCAA	GGATGTGAAC	GAGCGCCCAT	TATGGAAGGA	CCTACACGAT	2280
GTTAAGAAAT	GGGTCTTTTA	CAATGGAATG	GAGAAAAACG	AACAAATATC	ACCAGAGGCT	2340
CATCCAAACC	TTAAGATATT	CAGAAGTGAA	TCCGACGATG	CTGAAAGGAG	AAAGCATTGG	2400
AAGTATTGGG	AAGTTGCCGT	GGAAAGATCC	AAAGGTTGGC	TGAAGGACAT	AGAAGGTGAA	2460

CACGAACAGG TTCTAGAAAA CTTCCAATAA CAACATAAAT AATTTCTATT AACAATGTAA 2520

- (2) INFORMATION FOR SEQ ID NO:7:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 391 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: unknown
 - (D) TOPOLOGY: unknown
 - (ii) MOLECULE TYPE: protein
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

Met Ser Ala Ala Ala Asp Arg Leu Asn Leu Thr Ser Gly His Leu Asn 1 5 10 15

Ala Gly Arg Lys Arg Ser Ser Ser Val Ser Leu Lys Ala Ala Glu 20 25 30

Lys Pro Phe Lys Val Thr Val Ile Gly Ser Gly Asn Trp Gly Thr Thr 35 40 45

Ile Ala Lys Val Val Ala Glu Asn Cys Lys Gly Tyr Pro Glu Val Phe
50
55
60

Ala Pro Ile Val Gln Met Trp Val Phe Glu Glu Glu Ile Asn Gly Glu 65 70 75 80

Lys Leu Thr Glu Ile Ile Asn Thr Arg His Gln Asn Val Lys Tyr Leu 85 90 95

Pro Gly Ile Thr Leu Pro Asp Asn Leu Val Ala Asn Pro Asp Leu Ile 100 105 110

Asp Ser Val Lys Asp Val Asp IIe IIe Val Phe Asn Ile Pro His Gln 115 120 125

Phe Leu Pro Arg Ile Cys Ser Gln Leu Lys Gly His Val Asp Ser His 130 135 140

Val Arg Ala Ile Ser Cys Leu Lys Gly Phe Glu Val Gly Ala Lys Gly 145 150 155 160

Val Gln Leu Leu Ser Ser Tyr Ile Thr Glu Glu Leu Gly Ile Gln Cys 165 170 175

Gly Ala Leu Ser Gly Ala Asn Ile Ala Thr Glu Val Ala Gln Glu His 180 185 190

Trp Ser Glu Thr Thr Val Ala Tyr His Ile Pro Lys Asp Phe Arg Gly
195 200 205

Glu Gly Lys Asp Val Asp His Lys Val Leu Lys Ala Leu Phe His Arg 210 215 220

Pro Tyr Phe His Val Ser Val Ile Glu Asp Val Ala Gly Ile Ser Ile 225 230 235 240

Cys Gly Ala Leu Lys Asn Val Val Ala Leu Gly Cys Gly Phe Val Glu 245 250 255

- Gly Leu Gly Trp Gly Asn Asn Ala Ser Ala Ala Ile Gln Arg Val Gly 260 265 270
- Leu Gly Glu Ile Ile Arg Phe Gly Gln Met Phe Pro Glu Ser Arg 275 280 285
- Glu Glu Thr Tyr Tyr Gln Glu Ser Ala Gly Val Ala Asp Leu Ile Thr 290 295 300
- Thr Cys Ala Gly Gly Arg Asn Val Lys Val Ala Arg Leu Met Ala Thr 305 310 315 320
- Ser Gly Lys Asp Ala Trp Glu Cys Glu Lys Glu Leu Leu Asn Gly Gln
 325 330 335
- Ser Ala Gln Gly Leu Ile Thr Cys Lys Glu Val His Glu Trp Leu Glu 340 345 350
- Thr Cys Gly Ser Val Glu Asp Phe Pro Leu Phe Glu Ala Val Tyr Gln 355 360 365
- Ile Val Tyr Asn Asn Tyr Pro Met Lys Asn Leu Pro Asp Met Ile Glu 370 375 380

Glu Leu Asp Leu His Glu Asp 385 390

- (2) INFORMATION FOR SEQ ID NO:8:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 384 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: unknown
 - (D) TOPOLOGY: unknown
 - (ii) MOLECULE TYPE: protein
 - (xi) SEQUENCE DESCRIPTION: SEO ID NO:8:

Met Thr Ala His Thr Asn Ile Lys Gln His Lys His Cys His Glu Asp 1 5 10 15

His Pro Ile Arg Arg Ser Asp Ser Ala Val Ser Ile Val His Leu Lys 20 25 30

Arg Ala Pro Phe Lys Val Thr Val Ile Gly Ser Gly Asn Trp Gly Thr 35 40 45

Thr Ile Ala Lys Val Ile Ala Glu Asn Thr Glu Leu His Ser His Ile 50 55 60

Phe Glu Pro Glu Val Arg Met Trp Val Phe Asp Glu Lys Ile Gly Asp 65 · 70 75 80

Glu Asn Leu Thr Asp Ile Ile Asn Thr Arg His Gln Asn Val Lys Tyr 90 Leu Pro Asn Ile Asp Leu Pro His Asn Leu Val Ala Asp Pro Asp Leu 105 Leu His Ser Ile Lys Gly Ala Asp Ile Leu Val Phe Asn Ile Pro His Gln Phe Leu Pro Asn Ile Val Lys Gln Leu Gln Gly His Val Ala Pro 135 His Val Arg Ala Ile Ser Cys Leu Lys Gly Phe Glu Leu Gly Ser Lys 145 150 Gly Val Gln Leu Leu Ser Ser Tyr Val Thr Asp Glu Leu Gly Ile Gln 170 Cys Gly Ala Leu Ser Gly Ala Asn Leu Ala Pro Glu Val Ala Lys Glu 185 His Trp Ser Glu Thr Thr Val Ala Tyr Gln Leu Pro Lys Asp Tyr Gln 200 Gly Asp Gly Lys Asp Val Asp His Lys Ile Leu Lys Leu Leu Phe His 215 Arg Pro Tyr Phe His Val Asn Val Ile Asp Asp Val Ala Gly Ile Ser 230 Ile Ala Gly Ala Leu Lys Asn Val Val Ala Leu Ala Cys Gly Phe Val Glu Gly Met Gly Trp Gly Asn Asn Ala Ser Ala Ala Ile Gln Arg Leu Gly Leu Gly Glu Ile Ile Lys Phe Gly Arg Met Phe Phe Pro Glu Ser Lys Val Glu Thr Tyr Tyr Gln Glu Ser Ala Gly Val Ala Asp Leu Ile Thr Thr Cys Ser Gly Gly Arg Asn Val Lys Val Ala Thr Tyr Met Ala Lys Thr Gly Lys Ser Ala Leu Glu Ala Glu Lys Glu Leu Leu Asn Gly Gln Ser Ala Gln Gly Ile Ile Thr Cys Arg Glu Val His Glu Trp Leu Gln Thr Cys Glu Leu Thr Gln Glu Phe Pro Ile Ile Arg Gly Ser Leu Pro Asp Ser Leu Gln Gln Arg Pro His Gly Arg Pro Thr Gly Asp Asp 375

- (2) INFORMATION FOR SEQ ID NO:9:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 614 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: unknown
 - (D) TOPOLOGY: unknown
 - (ii) MOLECULE TYPE: protein
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

Met Thr Arg Ala Thr Trp Cys Asn Ser Pro Pro Pro Leu His Arg Gln 1 5 10

Val Ser Arg Arg Asp Leu Leu Asp Arg Leu Asp Lys Thr His Gln Phe 20 25 30

Asp Val Leu Ile Ile Gly Gly Gly Ala Thr Gly Thr Gly Cys Ala Leu $35 \hspace{1.5cm} 40 \hspace{1.5cm} 45$

Asp Ala Ala Thr Arg Gly Leu Asn Val Ala Leu Val Glu Lys Gly Asp 50 55 60

Phe Ala Ser Gly Thr Ser Ser Lys Ser Thr Lys Met Ile His Gly Gly 65 70 75 80

Val Arg Tyr Leu Glu Lys Ala Phe Trp Glu Phe Ser Lys Ala Gln Leu 85 90 95

Asp Leu Val Ile Glu Ala Leu Asn Glu Arg Lys His Leu Ile Asn Thr 100 105 110

Ala Pro His Leu Cys Thr Val Leu Pro Ile Leu Ile Pro Ile Tyr Ser 115 120 125

Thr Trp Gln Val Pro Tyr Ile Tyr Met Gly Cys Lys Phe Tyr Asp Phe 130 135 140

Phe Gly Gly Ser Gln Asn Leu Lys Lys Ser Tyr Leu Leu Ser Lys Ser 145 150 155 160

Ala Thr Val Glu Lys Ala Pro Met Leu Thr Thr Asp Asn Leu Lys Ala 165 170 175

Ser Leu Val Tyr Mis Asp Gly Ser Phe Asn Asp Ser Arg Leu Asn Ala 180 185 190

Thr Leu Ala Ile Thr Gly Val Glu Asn Gly Ala Thr Val Leu Ile Tyr 195 200 205

Val Glu Val Gln Lys Leu Ile Lys Asp Pro Thr Ser Gly Lys Val Ile 210 215 220

Gly Ala Glu Ala Arg Asp Val Glu Thr Asn Glu Leu Val Arg Ile Asn 225 230 235 240

Ala Lys Cys Val Val Asn Ala Thr Gly Pro Tyr Ser Asp Ala Ile Leu 250 245 Gln Met Asp Arg Asn Pro Ser Gly Leu Pro Asp Ser Pro Leu Asn Asp 265 Asn Ser Lys Ile Lys Ser Thr Phe Asn Gln Ile Ser Val Met Asp Pro Lys Met Val Ile Pro Ser Ile Gly Val His Ile Val Leu Pro Ser Phe Tyr Ser Pro Lys Asp Met Gly Leu Leu Asp Val Arg Thr Ser Asp Gly 310 Arg Val Met Phe Phe Leu Pro Trp Gln Gly Lys Val Leu Ala Gly Thr 325 330 Thr Asp Ile Pro Leu Lys Gln Val Pro Glu Asn Pro Met Pro Thr Glu 345 Ala Asp Ile Gln Asp Ile Leu Lys Glu Leu Gln His Tyr Ile Glu Phe 360 Pro Val Lys Arg Glu Asp Val Leu Ser Ala Trp Ala Gly Val Arg Pro Leu Val Arg Asp Pro Arg Thr Ile Pro Ala Asp Gly Lys Lys Gly Ser 390 Ala Thr Gln Gly Val Val Arg Ser His Phe Leu Phe Thr Ser Asp Asn 405 Gly Leu Ile Thr Ile Ala Gly Gly Lys Trp Thr Thr Tyr Arg Gln Met 425 Ala Glu Glu Thr Val Asp Lys Val Val Glu Val Gly Gly Phe His Asn Leu Lys Pro Cys His Thr Arg Asp Ile Lys Leu Ala Gly Ala Glu Glu Trp Thr Gln Asn Tyr Val Ala Leu Leu Ala Gln Asn Tyr His Leu Ser 470 Ser Lys Met Ser Asn Tyr Leu Val Gln Asn Tyr Gly Thr Arg Ser Ser Ile Ile Cys Glu Phe Phe Lys Glu Ser Met Glu Asn Lys Leu Pro Leu Ser Leu Ala Asp Lys Glu Asn Asn Val Ile Tyr Ser Ser Glu Glu Asn 520 Asn Leu Val Asn Phe Asp Thr Phe Arg Tyr Pro Phe Thr Ile Gly Glu 535 540

Leu Lys Tyr Ser Met Gln Tyr Glu Tyr Cys Arg Thr Pro Leu Asp Phe 545 550 560

Leu Leu Arg Arg Thr Arg Phe Ala Phe Leu Asp Ala Lys Glu Ala Leu 565 570 575

Asn Ala Val His Ala Thr Val Lys Val Met Gly Asp Glu Phe Asn Trp 580 585 590

Ser Glu Lys Lys Arg Gln Trp Glu Leu Glu Lys Thr Val Asn Phe Ile 595 600 605

Gln Gly Arg Phe Gly Val

- (2) INFORMATION FOR SEQ ID NO:10:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 339 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: unknown
 - (D) TOPOLOGY: unknown
 - (ii) MOLECULE TYPE: protein
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Met Asn Gln Arg Asn Ala Ser Met Thr Val Ile Gly Ala Gly Ser Tyr
1 5 10 15

Gly Thr Ala Leu Ala Ile Thr Leu Ala Arg Asn Gly His Glu Val Val 20 25 30

Leu Trp Gly His Asp Pro Glu His Ile Ala Thr Leu Glu Arg Asp Arg 35 40 45

Cys Asn Ala Ala Phe Leu Pro Asp Val Pro Phe Pro Asp Thr Leu His 50 55 60

Leu Glu Ser Asp Leu Ala Thr Ala Leu Ala Ala Ser Arg Asn Ile Leu 65 70 75 80.

Val Val Val Pro Ser His Val Phe Gly Glu Val Leu Arg Gln Ile Lys 85 90 95

Pro Leu Met Arg Pro Asp Ala Arg Leu Val Trp Ala Thr Lys Gly Leu 100 105 110

Glu Ala Glu Thr Gly Arg Leu Leu Gln Asp Val Ala Arg Glu Ala Leu 115 120 125

Gly Asp Gln Ile Pro Leu Ala Val Ile Ser Gly Pro Thr Phe Ala Lys 130 135 140

Glu Leu Ala Ala Gly Leu Pro Thr Ala Ile Ser Leu Ala Ser Thr Asp 145 150 155 160

Gln Thr Phe Ala Asp Asp Leu Gln Gln Leu Leu His Cys Gly Lys Ser 165 170 175

- Phe Arg Val Tyr Ser Asn Pro Asp Phe Ile Gly Val Gln Leu Gly Gly 180 * 185 190
- Ala Val Lys Asn Val Ile Ala Ile Gly Ala Gly Met Ser Asp Gly Ile 195 200 205
- Gly Phe Gly Ala Asn Ala Arg Thr Ala Leu Ile Thr Arg Gly Leu Ala 210 215 220
- Glu Met Ser Arg Leu Gly Ala Ala Leu Gly Ala Asp Pro Ala Thr Phe 225 230 235 240
- Met Gly Met Ala Gly Leu Gly Asp Leu Val Leu Thr Cys Thr Asp Asn 245 250 255
- Gln Ser Arg Asn Arg Arg Phe Gly Met Met Leu Gly Gln Gly Met Asp 260 265 270
- Val Gln Ser Ala Gln Glu Lys Ile Gly Gln Val Val Glu Gly Tyr Arg 275 280 285
- Asn Thr Lys Glu Val Arg Glu Leu Ala His Arg Phe Gly Val Glu Met 290 295 300
- Pro Ile Thr Glu Glu Ile Tyr Gln Val Leu Tyr Cys Gly Lys Asn Ala 305 310 315 320
- Arg Glu Ala Ala Leu Thr Leu Leu Gly Arg Ala Arg Lys Asp Glu Arg 325 330 335

Ser Ser His

- (2) INFORMATION FOR SEQ ID NO:11:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 501 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: unknown
 - (D) TOPOLOGY: unknown
 - (ii) MOLECULE TYPE: protein
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:
- Met Glu Thr Lys Asp Leu Ile Val Ile Gly Gly Gly Ile Asn Gly Ala 1 5 10 15
- Gly Ile Ala Ala Asp Ala Ala Gly Arg Gly Leu Ser Val Leu Met Leu 20 25 30
- Glu Ala Gln Asp Leu Ala Cys Ala Thr Ser Ser Ala Ser Ser Lys Leu 35 . 40
- Ile His Gly Gly Leu Arg Tyr Leu Glu His Tyr Glu Phe Arg Leu Val 50 55 60

Ser Glu Ala Leu Ala Glu Arg Glu Val Leu Leu Lys Met Ala Pro His 70 Ile Ala Phe Pro Met Arg Phe Arg Leu Pro His Arg Pro His Leu Arg 90 Pro Ala Trp Met Ile Arg Ile Gly Leu Phe Met Tyr Asp His Leu Gly 105 Lys Arg Thr Ser Leu Pro Gly Ser Thr Gly Leu Arg Phe Gly Ala Asn Ser Val Leu Lys Pro Glu Ile Lys Arg Gly Phe Glu Tyr Ser Asp Cys 135 Trp Val Asp Asp Ala Arg Leu Val Leu Ala Asn Ala Gln Met Val Val Arg Lys Gly Gly Glu Val Leu Thr Arg Thr Arg Ala Thr Ser Ala Arg 170 Arg Glu Asn Gly Leu Trp Ile Val Glu Ala Glu Asp Ile Asp Thr Gly 180 . 185 Lys Lys Tyr Ser Trp Gln Ala Arg Gly Leu Val Asn Ala Thr Gly Pro 200 Trp Val Lys Gln Phe Phe Asp Asp Gly Met His Leu Pro Ser Pro Tyr Gly Ile Arg Leu Ile Lys Gly Ser His Ile Val Val Pro Arg Val His Thr Gln Lys Gln Ala Tyr Ile Leu Gln Asn Glu Asp Lys Arg Ile Val Phe Val Ile Pro Trp Met Asp Glu Phe Ser Ile Ile Gly Thr Thr Asp Val Glu Tyr Lys Gly Asp Pro Lys Ala Val Lys Ile Glu Glu Ser Glu Ile Asn Tyr Leu Leu Asn Val Tyr Asn Thr His Phe Lys Lys Gln Leu Ser Arg Asp Asp Ile Val Trp Thr Tyr Ser Gly Val Arg Pro Leu Cys 310 315 Asp Asp Glu Ser Asp Ser Pro Gln Ala Ile Thr Arg Asp Tyr Thr Leu Asp Ile His Asp Glu Asn Gly Lys Ala Pro Leu Leu Ser Val Phe Gly 345 Gly Lys Leu Thr Thr Tyr Arg Lys Leu Ala Glu His Ala Leu Glu Lys 355 360

Leu Thr Pro Tyr Tyr Gln Gly Ile Gly Pro Ala Trp Thr Lys Glu Ser 370 375 380

Val Leu Pro Gly Gly Ala Ile Glu Gly Asp Arg Asp Asp Tyr Ala Ala 385 390 395 400

Arg Leu Arg Arg Tyr Pro Phe Leu Thr Glu Ser Leu Ala Arg His
405 410 415

Tyr Ala Arg Thr Tyr Gly Ser Asn Ser Glu Leu Leu Gly Asn Ala
420 425 430

Gly Thr Val Ser Asp Leu Gly Glu Asp Phe Gly His Glu Phe Tyr Glu 435 440 445

Ala Glu Leu Lys Tyr Leu Val Asp His Glu Trp Val Arg Arg Ala Asp 450 460

Asp Ala Leu Trp Arg Arg Thr Lys Gln Gly Met Trp Leu Asn Ala Asp 465 470 475 480

Gln Gln Ser Arg Val Ser Gln Trp Leu Val Glu Tyr Thr Gln Gln Arg
485 490 495

Leu Ser Leu Ala Ser 500

- (2) INFORMATION FOR SEQ ID NO:12:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 542 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: unknown
 - (D) TOPOLOGY: unknown
 - (ii) MOLECULE TYPE: protein
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

Met Lys Thr Arg Asp Ser Gln Ser Ser Asp Val Ile Ile Gly Gly 1 5 10 15

Gly Ala Thr Gly Ala Gly Ile Ala Arg Asp Cys Ala Leu Arg Gly Leu 20 25 30

Arg Val Ile Leu Val Glu Arg His Asp Ile Ala Thr Gly Ala Thr Gly 35 40

Arg Asn His Gly Leu Leu His Ser Gly Ala Arg Tyr Ala Val Thr Asp 50 55 60

Ala Glu Ser Ala Arg Glu Cys Ile Ser Glu Asn Gln Ile Leu Lys Arg 65 70 75 80

Ile Ala Arg His Cys Val Glu Pro Thr Asn Gly Leu Phe Ile Thr Leu 85 90 95

Pro Glu Asp Asp Leu Ser Phe Gln Ala Thr Phe Ile Arg Ala Cys Glu 105 Glu Ala Gly Ile Ser Ala Glu Ala Ile Asp Pro Gln Gln Ala Arg Ile 120 Ile Glu Pro Ala Val Asn Pro Ala Leu Ile Gly Ala Val Lys Val Pro 135 Asp Gly Thr Val Asp Pro Phe Arg Leu Thr Ala Ala Asn Met Leu Asp 150 155 Ala Lys Glu His Gly Ala Val Ile Leu Thr Ala His Glu Val Thr Gly 170 Leu Ile Arg Glu Gly Ala Thr Val Cys Gly Val Arg Val Arg Asn His Leu Thr Gly Glu Thr Gln Ala Leu His Ala Pro Val Val Val Asn Ala Ala Gly Ile Trp Gly Gln His Ile Ala Glu Tyr Ala Asp Leu Arg Ile 215 Arg Met Phe Pro Ala Lys Gly Ser Leu Leu Ile Met Asp His Arg Ile Asn Gln His Val Ile Asn Arg Cys Arg Lys Pro Ser Asp Ala Asp Ile Leu Val Pro Gly Asp Thr Ile Ser Leu Ile Gly Thr Thr Ser Leu Arg Ile Asp Tyr Asn Glu Ile Asp Asp Asn Arg Val Thr Ala Glu Glu Val 280 Asp Ile Leu Leu Arg Glu Gly Glu Lys Leu Ala Pro Val Met Ala Lys 295 Thr Arg Ile Leu Arg Ala Tyr Ser Gly Val Arg Pro Leu Val Ala Ser 310 315 Asp Asp Asp Pro Ser Gly Arg Asn Leu Ser Arg Gly Ile Val Leu Leu Asp His Ala Glu Arg Asp Gly Leu Asp Gly Phe Ile Thr Ile Thr Gly 345 Gly Lys Leu Met Thr Tyr Arg Leu Met Ala Glu Trp Ala Thr Asp Ala 355 Val Cys Arg Lys Leu Gly Asn Thr Arg Pro Cys Thr Thr Ala Asp Leu Ala Leu Pro Gly Ser Gln Glu Pro Ala Glu Val Thr Leu Arg Lys Val 385 390 395

Ile Ser Leu Pro Ala Pro Leu Arg Gly Ser Ala Val Tyr Arg His Gly
405 410 415

- Asp Arg Thr Pro Ala Trp Leu Ser Glu Gly Arg Leu His Arg Ser Leu 420 425 430
- Val Cys Glu Cys Glu Ala Val Thr Ala Gly Glu Val Gln Tyr Ala Val 435 440 445
- Glu Asn Leu Asn Val Asn Ser Leu Leu Asp Leu Arg Arg Arg Thr Arg 450 455 460
- Val Gly Met Gly Thr Cys Gln Gly Glu Leu Cys Ala Cys Arg Ala Ala 465 470 475 480
- Gly Leu Leu Gln Arg Phe Asn Val Thr Thr Ser Ala Gln Ser Ile Glu 485 490 495
- Gln Leu Ser Thr Phe Leu Asn Glu Arg Trp Lys Gly Val Gln Pro Ile 500 505 510
- Ala Trp Gly Asp Ala Leu Arg Glu Ser Glu Phe Thr Arg Trp Val Tyr 515 520 525
- Gln Gly Leu Cys Gly Leu Glu Lys Glu Gln Lys Asp Ala Leu 530 540
- (2) INFORMATION FOR SEQ ID NO:13:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 250 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: unknown
 - (D) TOPOLOGY: unknown
 - (ii) MOLECULE TYPE: protein
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

Met Gly Leu Thr Thr Lys Pro Leu Ser Leu Lys Val Asn Ala Ala Leu 1 5 10 15

Phe Asp Val Asp Gly Thr Ile Ile Ile Ser Gln Pro Ala Ile Ala Ala 20 25 30

Phe Trp Arg Asp Phe Gly Lys Asp Lys Pro Tyr Phe Asp Ala Glu His

Val Ile Gln Val Ser His Gly Trp Arg Thr Phe Asp Ala Ile Ala Lys 50 55 60

Phe Ala Pro Asp Phe Ala Asn Glu Glu Tyr Val Asn Lys Leu Glu Ala 65 70 75 80

Glu Ile Pro Val Lys Tyr Gly Glu Lys Ser Ile Glu Val Pro Gly Ala 85 90 95

Val Lys Leu Cys Asn Ala Leu Asn Ala Leu Pro Lys Glu Lys Trp Ala 100 105 110

- Val Ala Thr Ser Gly Thr Arg Asp Met Ala Gln Lys Trp Phe Glu His
 115 120 125
- Leu Gly Ile Arg Arg Pro Lys Tyr Phe Ile Thr Ala Asn Asp Val Lys 130 135 140
- Gln Gly Lys Pro His Pro Glu Pro Tyr Leu Lys Gly Arg Asn Gly Leu 145 150 155 160
- Gly Tyr Pro Ile Asn Glu Gln Asp Pro Ser Lys Ser Lys Val Val Val 165 170 175
- Phe Glu Asp Ala Pro Ala Gly Ile Ala Ala Gly Lys Ala Ala Gly Cys 180 185 190
- Lys Ile Ile Gly Ile Ala Thr Thr Phe Asp Leu Asp Phe Leu Lys Glu 195 200 205
- Lys Gly Cys Asp Ile Ile Val Lys Asn His Glu Ser Ile Arg Val Gly 210 215 220
- Gly Tyr Asn Ala Glu Thr Asp Glu Val Glu Phe Ile Phe Asp Asp Tyr 225 . 230 235 240

Leu Tyr Ala Lys Asp Asp Leu Leu Lys Trp 245 250

- (2) INFORMATION FOR SEQ ID NO:14:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 271 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: unknown
 - (D) TOPOLOGY: unknown
 - (ii) MOLECULE TYPE: protein
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

Met Lys Arg Phe Asn Val Leu Lys Tyr Ile Arg Thr Thr Lys Ala Asn 1 5 10 15

Ile Gln Thr Ile Ala Met Pro Leu Thr Thr Lys Pro Leu Ser Leu Lys 20 25 30

Ile Asn Ala Ala Leu Phe Asp Val Asp Gly Thr Ile Ile Ser Gln 35 40 45

Pro Ala Ile Ala Ala Phe Trp Arg Asp Phe Gly Lys Asp Lys Pro Tyr 50 55 60

Phe Asp Ala Glu His Val Ile His Ile Ser His Gly Trp Arg Thr Tyr 65 70 75 80

Asp Ala Ile Ala Lys Phe Ala Pro Asp Phe Ala Asp Glu Glu Tyr Val 85 90 95

- Asn Lys Leu Glu Gly Glu Ile Pro Glu Lys Tyr Gly Glu His Ser Ile 100 105 110
- Glu Val Pro Gly Ala Val Lys Leu Cys Asn Ala Leu Asn Ala Leu Pro 115 120 125
- Lys Glu Lys Trp Ala Val Ala Thr Ser Gly Thr Arg Asp Met Ala Lys 130 135 140
- Lys Trp Phe Asp Ile Leu Lys Ile Lys Arg Pro Glu Tyr Phe Ile Thr 145 150 155 160
- Ala Asn Asp Val Lys Gln Gly Lys Pro His Pro Glu Pro Tyr Leu Lys 165 170 175
- Gly Arg Asn Gly Leu Gly Phe Pro Ile Asn Glu Gln Asp Pro Ser Lys 180 . 185 190
- Ser Lys Val Val Val Phe Glu Asp Ala Pro Ala Gly Ile Ala Ala Gly 195 200 205
- Lys Ala Ala Gly Cys Lys Ile Val Gly Ile Ala Thr Thr Phe Asp Leu 210 215 220
- Asp Phe Leu Lys Glu Lys Gly Cys Asp Ile Ile Val Lys Asn His Glu 225 230 235 240
- Ser Ile Arg Val Gly Glu Tyr Asn Ala Glu Thr Asp Glu Val Glu Leu 245 250 255
- Ile Phe Asp Asp Tyr Leu Tyr Ala Lys Asp Asp Leu Leu Lys Trp
 260 265 270
- (2) INFORMATION FOR SEQ ID NO:15:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 709 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: unknown
 - (D) TOPOLOGY: unknown
 - (ii) MOLECULE TYPE: protein
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

Met Phe Pro Ser Leu Phe Arg Leu Val Val Phe Ser Lys Arg Tyr Ile 1 5 10 15

Phe Arg Ser Ser Gln Arg Leu Tyr Thr Ser Leu Lys Gln Glu Gln Ser 20 25 30

Arg Met Ser Lys Ile Met Glu Asp Leu Arg Ser Asp Tyr Val Pro Leu 35 40 45

Ile Ala Ser Ile Asp Val Gly Thr Thr Ser Ser Arg Cys Ile Leu Phe Asn Arg Trp Gly Gln Asp Val Ser Lys His Gln Ile Glu Tyr Ser Thr Ser Ala Ser Lys Gly Lys Ile Gly Val Ser Gly Leu Arg Arg Pro Ser Thr Ala Pro Ala Arg Glu Thr Pro Asn Ala Gly Asp Ile Lys Thr Ser 105 Gly Lys Pro Ile Phe Ser Ala Glu Gly Tyr Ala Ile Gln Glu Thr Lys 120 Phe Leu Lys Ile Glu Glu Leu Asp Leu Asp Phe His Asn Glu Pro Thr Leu Lys Phe Pro Lys Pro Gly Trp Val Glu Cys His Pro Gln Lys Leu Leu Val Asn Val Val Gln Cys Leu Ala Ser Ser Leu Leu Ser Leu Gln Thr Ile Asn Ser Glu Arg Val Ala Asn Gly Leu Pro Pro Tyr Lys Val Ile Cys Met Gly Ile Ala Asn Met Arg Glu Thr Thr Ile Leu Trp Ser Arg Arg Thr Gly Lys Pro Ile Val Asn Tyr Gly Ile Val Trp Asn Asp 215 Thr Arg Thr Ile Lys Ile Val Arg Asp Lys Trp Gln Asn Thr Ser Val Asp Arg Gln Leu Gln Leu Arg Gln Lys Thr Gly Leu Pro Leu Leu Ser 250 Thr Tyr Phe Ser Cys Ser Lys Leu Arg Trp Phe Leu Asp Asn Glu Pro 265 Leu Cys Thr Lys Ala Tyr Glu Glu Asn Asp Leu Met Phe Gly Thr Val 275 280 Asp Thr Trp Leu Ile Tyr Gln Leu Thr Lys Gln Lys Ala Phe Val Ser Asp Val Thr Asn Ala Ser Arg Thr Gly Phe Met Asn Leu Ser Thr Leu 305 310 315 Lys Tyr Asp Asn Glu Leu Leu Glu Phe Trp Gly Ile Asp Lys Asn Leu Ile His Met Pro Glu Ile Val Ser Ser Ser Gln Tyr Tyr Gly Asp Phe 340 345

Gly Ile Pro Asp Trp Ile Met Glu Lys Leu His Asp Ser Pro Lys Thr 360 Val Leu Arg Asp Leu Val Lys Arg Asn Leu Pro Ile Gln Gly Cys Leu 375 Gly Asp Gln Ser Ala Ser Met Val Gly Gln Leu Ala Tyr Lys Pro Gly Ala Ala Lys Cys Thr Tyr Gly Thr Gly Cys Phe Leu Leu Tyr Asn Thr 410 Gly Thr Lys Lys Leu Ile Ser Gln His Gly Ala Leu Thr Thr Leu Ala 425 Phe Trp Phe Pro His Leu Gln Glu Tyr Gly Gly Gln Lys Pro Glu Leu Ser Lys Pro His Phe Ala Leu Glu Gly Ser Val Ala Val Ala Gly Ala 455 Val Val Gln Trp Leu Arg Asp Asn Leu Arg Leu Ile Asp Lys Ser Glu 470 475 Asp Val Gly Pro Ile Ala Ser Thr Val Pro Asp Ser Gly Gly Val Val 485 490 Phe Val Pro Ala Phe Ser Gly Leu Phe Ala Pro Tyr Trp Asp Pro Asp 505 Ala Arg Ala Thr Ile Met Gly Met Ser Gln Phe Thr Thr Ala Ser His 515 Ile Ala Arg Ala Ala Val Glu Gly Val Cys Phe Gln Ala Arg Ala Ile 535 Leu Lys Ala Met Ser Ser Asp Ala Phe Gly Glu Gly Ser Lys Asp Arg 545 Asp Phe Leu Glu Glu Ile Ser Asp Val Thr Tyr Glu Lys Ser Pro Leu Ser Val Leu Ala Val Asp Gly Gly Met Ser Arg Ser Asn Glu Val Met Gln Ile Gln Ala Asp Ile Leu Gly Pro Cys Val Lys Val Arg Arg Ser Pro Thr Ala Glu Cys Thr Ala Leu Gly Ala Ala Ile Ala Ala Asn Met 615 Ala Phe Lys Asp Val Asn Glu Arg Pro Leu Trp Lys Asp Leu His Asp Val Lys Lys Trp Val Phe Tyr Asn Gly Met Glu Lys Asn Glu Gln Ile 645 650

660 665	670
Asp Ala Glu Arg Arg Lys His Trp Lys Tyr 1	Irp Glu Val Ala Val Glu 685
Arg Ser Lys Gly Trp Leu Lys Asp Ile Glu (Gly Glu His Glu Gln Val 700
Leu Glu Asn Phe Gln 705	
(2) INFORMATION FOR SEQ ID NO:16:	
 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 51 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 	
(ii) MOLECULE TYPE: DNA (genomic)	
(xi) SEQUENCE DESCRIPTION: SEQ ID	NO:16:
GCGCGGATCC AGGAGTCTAG AATTATGGGA TTGACTAG	CTA AACCTCTATC T 51
(2) INFORMATION FOR SEQ ID NO:17:	
 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 36 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 	
(ii) MOLECULE TYPE: DNA (genomic)	
(xi) SEQUENCE DESCRIPTION: SEQ ID	NO:17:
GATACGCCCG GGTTACCATT TCAACAGATC GTCCTT	36
(2) INFORMATION FOR SEQ ID NO:18:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 34 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(ii) MOLECULE TYPE: DNA (genomic)	
(xi) SEQUENCE DESCRIPTION: SEQ ID	NO:18:
TTGATAATAT AACCATGGCT GCTGCTGCTG ATAG	34

(2) INFO	RMATION FOR SEQ ID NO:19:	
(i)	SEQUENCE CHARACTERISTICS: (A) LENGTH: 39 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(ii)	MOLECULE TYPE: DNA (genomic)	
(xi)	SEQUENCE DESCRIPTION: SEQ ID NO:19:	
GTATGATATG	TTATCTTGGA TCCAATAAAT CTAATCTTC	39
(2) INFO	RMATION FOR SEQ ID NO:20:	
(i)	SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(ii)	MOLECULE TYPE: DNA (genomic)	
(xi)	SEQUENCE DESCRIPTION: SEQ ID NO:20:	
CATGACTAGT	AAGGAGGACA ATTC	24
(2) INFO	RMATION FOR SEQ ID NO:21:	
(i)	SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(ii)	MOLECULE TYPE: DNA (genomic)	
(xi)	SEQUENCE DESCRIPTION: SEQ ID NO:21:	
CATGGAATTG	TCCTCCTTAC TAGT	24
(2) INFO	RMATION FOR SEQ ID NO:22:	
(i)	SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(ii)	MOLECULE TYPE: DNA (genomic)	
(xi)	SEQUENCE DESCRIPTION: SEQ ID NO:22:	
CTAGTAAGGA	GGACAATTC	19

(2)	INFO	RMATION FOR SEQ ID NO:23:	
	i)	SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(i	.i)	MOLECULE TYPE: DNA (genomic)	
(х	(i)	SEQUENCE DESCRIPTION: SEQ ID NO:23:	
CATGGA	ATTG	TCCTCCTTA	19
(2)	INFO	RMATION FOR SEQ ID NO:24:	
. ((i)	SEQUENCE CHARACTERISTICS: (A) LENGTH: 15 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(i	•	MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "PRIMER"	
(ii	Li)	HYPOTHETICAL: NO	
(i	LV)	ANTI-SENSE: NO	
(х	ki)	SEQUENCE DESCRIPTION: SEQ ID NO:24:	
GATCCA	GGAA	ACAGA	15
(2)	INFO	RMATION FOR SEQ ID NO:25:	
((i)	SEQUENCE CHARACTERISTICS: (A) LENGTH: 15 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(i	ii)	MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "PRIMER"	
(ii	ii)	HYPOTHETICAL: NO	
(i	i v)	ANTI-SENSE: NO	
k)	(i)	SEQUENCE DESCRIPTION: SEQ ID NO:25:	
CTAGTC	TGTT	TCCTG	15
(2)	INFO	RMATION FOR SEQ ID NO:26:	
((i)	SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	

(ii)	MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "PRIMER"	
(xi)	SEQUENCE DESCRIPTION: SEQ ID NO:26:	
GCTTTCTGT	G CTGCGGCTTT AG	22
(2) INF	ORMATION FOR SEQ ID NO:27:	
(i)	SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(ii)	MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "PRIMER"	
(xi)	SEQUENCE DESCRIPTION: SEQ ID NO:27:	
TGGTCGAGG	A TCCACTTCAC TTT	23
(2) INF	ORMATION FOR SEQ ID NO:28:	
(i)	SEQUENCE CHARACTERISTICS: (A) LENGTH: 51 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(ii)	MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "PRIMER"	
(xi)	SEQUENCE DESCRIPTION: SEQ ID NO:28:	
AAAGTGAAG	ET GGATCCTCGA CCAATTGGAT GGTGGCGCAG TAGCAAACAA T	51
(2) INE	CORMATION FOR SEQ ID NO:29:	
(i)	SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(ii)	MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "PRIMER"	
(xi)	SEQUENCE DESCRIPTION: SEQ ID NO:29:	
GGATCACCO	GC CGCAGAAACT ACG	23
(2) INF	FORMATION FOR SEQ ID NO:30:	
(i)	SEQUENCE CHARACTERISTICS: (A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(ii)	MOLECULE TYPE: other nucleic acid	

(X1)	SEQUENCE DESCRIPTION: SEQ ID NO:30:	
CTGTCAGCC	TTAAGTGTTC CTGTG	25
(2) INFO	DRMATION FOR SEQ ID NO:31:	
(i)	SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(ii)	MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "PRIMER"	
(xi)	SEQUENCE DESCRIPTION: SEQ ID NO:31:	
CAGTTCAAC	C TGTTGATAGT ACG	23
(2) INF	ORMATION FOR SEQ ID NO:32:	
(i)	SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(ii)	MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "PRIMER"	
(xi)	SEQUENCE DESCRIPTION: SEQ ID NO:32:	
ATGAGTCAA	A CATCAACCTT	20
	A CATCAACCTT ORMATION FOR SEQ ID NO:33:	20
		20
(2) INF	SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	20
(2) INF	SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "PRIMER"	20
(2) INFO (ii) (iii) (xi)	SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "PRIMER"	20
(2) INFO (ii) (ii) (xi) ATGGAGAAA	SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "PRIMER" SEQUENCE DESCRIPTION: SEQ ID NO:33:	
(2) INFO (ii) (ii) (xi) ATGGAGAAA	SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "PRIMER" SEQUENCE DESCRIPTION: SEQ ID NO:33: A AAATCACTGG	
(2) INFO (ii) (xi) ATGGAGAAA (2) INF	SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "PRIMER" SEQUENCE DESCRIPTION: SEQ ID NO:33: A AAATCACTGG ORMATION FOR SEQ ID NO:34: SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single	
(2) INFO (ii) (xi) ATGGAGAAA (2) INFO (ii)	SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "PRIMER" SEQUENCE DESCRIPTION: SEQ ID NO:33: A AAATCACTGG ORMATION FOR SEQ ID NO:34: SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear MOLECULE TYPE: other nucleic acid	

(2)	INFO.	RMATION FOR SEQ ID NO:35:	
	(i)	SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
	(ii)	MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "PRIMER"	
	(xi)	SEQUENCE DESCRIPTION: SEQ ID NO:35:	
TCAG	AGGATG	TGCACCTGCA	20
(2)	INFO	RMATION FOR SEQ ID NO:36:	
	(i)	SEQUENCE CHARACTERISTICS: (A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
	(ii)	MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "PRIMER"	
	(xi)	SEQUENCE DESCRIPTION: SEQ ID NO:36:	
CGAG	CATGCC	GCATTTGGCA CTACTC	26
(2)	INFO	RMATION FOR SEQ ID NO:37:	
	(i)	SEQUENCE CHARACTERISTICS: (A) LENGTH: 29 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
	(ii)	MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "PRIMER"	
	(xi)	SEQUENCE DESCRIPTION: SEQ ID NO:37:	
GCGT	'CTAGAG	TAGGTTATTC CCACTCTTG	29
(2)	INFO	RMATION FOR SEQ ID NO:38:	
	(i)	SEQUENCE CHARACTERISTICS: (A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
	(ii)	MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "PRIMER"	
	(xi)	SEQUENCE DESCRIPTION: SEQ ID NO:38:	
GAAG	TCGACC	GCTGCGCCTT ATCCGG	26

(2) INFO	RMATION FOR SEQ ID NO:39:	
(i)	SEQUENCE CHARACTERISTICS: (A) LENGTH: 28 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(ii)	MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "PRIMER"	
(xi)	SEQUENCE DESCRIPTION: SEQ ID NO:39:	
CGCGTCGACG	TTTACAATTT CAGGTGGC	28
(2) INFO	RMATION FOR SEQ ID NO:40:	
(i)	SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(ii)	MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "PRIMER"	
(xi)	SEQUENCE DESCRIPTION: SEQ ID NO:40:	
GCAGCATGCT	GGACTGGTAG TAG	23
(2) INFO	RMATION FOR SEQ ID NO:41:	
(i)	SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(ii)	MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "PRIMER"	
(xi)	SEQUENCE DESCRIPTION: SEQ ID NO:41:	
CAGTCTAGAG	TTATTGGCAA ACCTACC	27
(2) INFO	RMATION FOR SEQ ID NO:42:	
(i)	SEQUENCE CHARACTERISTICS: (A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(ii)	MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "PRIMER"	
(xi)	SEQUENCE DESCRIPTION: SEQ ID NO:42:	
GATGCATGCC	CAGGGCGGAG ACGGC	25

(2) INFO	DRMATION FOR SEQ ID NO:43:	
(i)	SEQUENCE CHARACTERISTICS: (A) LENGTH: 29 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(ii)	MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "PRIMER"	
(xi)	SEQUENCE DESCRIPTION: SEQ ID NO:43:	
CTAACGATTO	G TTCTCTAGAG AAAATGTCC	29
(2) INFO	ORMATION FOR SEQ ID NO:44:	
(i)	SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(ii)	MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "primer"	
(iii)	HYPOTHETICAL: NO	
(iv)	ANTI-SENSE: NO	
(xi)	SEQUENCE DESCRIPTION: SEQ ID NO:44:	
CACGCATGC	A GTTCAACCTG TTGATAGTAC	30
(2) INF	ORMATION FOR SEQ ID NO:45:	
(i)	SEQUENCE CHARACTERISTICS: (A) LENGTH: 28 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(ii)	MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "primer"	
(iii)	HYPOTHETICAL: NO	
(iv)	ANTI-SENSE: NO	
(xi)	SEQUENCE DESCRIPTION: SEQ ID NO:45:	
GCGTCTAGA	T CCTTTTAAAT TAAAAATG	28

Inte. anal Application No PCT/US 98/25551

A. CLASSIF IPC 6	C12N15/53 C12N15/55 C12N15/53 C12N15/55 C12N1/15 C12N1/19 C12N9/88	C12N15/60 C12N1/21	C12P7/20 C12N9/04	
According to	International Patent Classification (IPC) or to both n	ational classification a	nd IPC	,
B. FIELDS				
Minimum do IPC 6	cumentation searched (classification system followe C12N C12P	d by classification syn	nbols)	
***	lon searched other than minimum documentation to			
	ata base consulted during the international search (r	lame of data base and	i, where practical, searc	n terms used)
	ENTS CONSIDERED TO BE RELEVANT			
Category °	Citation of document, with indication, where appro	priate, of the relevant	passages	Relevant to claim No.
A	WANG HT. ET AL.: "Clorand disruption of Sacchardiastaticus DAR1 gene englycerol-3-phosphate dehy JOURNAL OF BACTERIOLOGY, vol. 176, no. 22, Novemb 7091-7095, XP000563880 cited in the application see abstract see page 7091, column 2,	romyces coding a ydrogenase.' er 1994, pag	ges 2	1-16
X Furt	her documents are listed in the continuation of box (c. <u>X</u>	Patent family memb	pers are listed in annex.
"A" docum conside "E" earler filing of "L" docum which critatio "O" docum other "P" docum later t	ategories of cited documents: ent defining the general state of the art which is not dered to be of particular relevance document but published on or after the international date ent which may throw doubts on priority claim(s) or is cited to establish the publication date of another on or other special reason (as specified) ent referring to an oral disclosure, use, exhibition or means ent published prior to the international filing date but than the priority date claimed	-v-	or priority date and not incited to understand the invention document of particular recannot be considered involve an inventive steed document of particular recannot be considered to document is combined ments, such combination the art.	I after the international filing date in conflict with the application but principle or theory underlying the elevance; the claimed invention ovel or cannot be considered to p when the document is taken alone between the claimed invention or involve an inventive step when the with one or more other such document being obvious to a person skilled as same patent family ternational search report
5	6 March 1999		12/03/1999)
Name and	mailing address of the ISA European Patent Office, P.B. 5818 Patentiaan NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	2 .	Authorized officer Hornig, H	

1

Inte onal Application No PCT/US 98/25551

	<u> </u>	PC1/US 98/25551
	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	Relevant to claim No.
Category *	Citation of document, with indication, where appropriate, of the relevant passages	rielevant to claim No.
A	NORBECK J. ET AL.: "Purification and characterization of two isoenzymes of DL-glycerol-3-phosphatase from Saccharomyces cerevisiae." JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 23, 7 June 1996, pages 13875-13881, XP002058248 cited in the application see abstract see page 13875, column 2, paragraph 2 see page 13881, column 1, line 8 - line 21	1-16
A	HIRAYAMA T ET AL: "CLONING AND CHARACTERIZATION OF SEVEN CDNAS FOR HYPEROSMOLARITY- RESPONSIVE (HOR) GENES OF SACCHAROMYCES CEREVISIAE" MOLECULAR AND GENERAL GENETICS, vol. 249, 1995, pages 127-138, XP002058249 cited in the application see abstract see page 129, right-hand column, line 2; figure 1A	1-16
A	LARSSON K. ET AL.: "A gene encoding sn-glycerol 3-phosphate dehydrogenase (NAD+) complements an osmosensitive mutant of Saccharomyces cerevisiae." MOLECULAR MICROBIOLOGY, vol. 10, no. 5, 1993, pages 1101-1111, XP000562759 cited in the application see abstract	1-16
A	FR 2 735 145 A (AGRONOMIQUE INST NAT RECH) 13 December 1996 see claims 1-5	1-16
A	WO 97 07199 A (WISCONSIN ALUMNI RES FOUND) 27 February 1997 see claims 9-12	1-16
A	OMORI T. ET AL.: "Breeding of high glycerol-producing shochu yeast (Saccharomyces cerevisiae) with acquired salt tolerance." JOURNAL OF FERMENTATION AND BIOENGINEERING, vol. 79, no. 6, 1995, pages 560-565, XP002058250 see abstract	1-16
P,A	WO 98 21340 A (BULTHUIS BEN A ;HAYNIE SHARON LORETTA (US); HSU AMY KUANG HUA (US)) 22 May 1998 see the whole document	1-16

1

Inte onal Application No
PCT/US 98/25551

	·	PC1/US 98/25551
C.(Continue	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category '	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 96 35795 A (DU PONT ; NAGARAJAN VASANTHA (US); NAKAMURA CHARLES EDWIN (US)) 14 November 1996 see the whole document	17-20 .
A	WO 96 35796 A (DU PONT ;GENENCOR INT (US); LAFFEND LISA ANNE (US); NAGARAJAN VASA) 14 November 1996 see the whole document	17-20
A	WO 96 35799 A (DU PONT ;HAYNIE SHARON LORETTA (US); WAGNER LORRAINE WINONA (US)) 14 November 1996 see the whole document	17-20
P,A	WO 98 21339 A (DIAS TORRES MARIA ; HAYNIE SHARON LORETTA (US); HSU AMY KUANG HUA () 22 May 1998 see the whole document	17-20
P,A	WO 98 21341 A (DIAZ TORRES MARIA ;CHASE MATTHEW W (US); GENENCOR INT (US); TRIMBU) 22 May 1998 see the whole document	17-20

1

ij

information on patent family members

Int. Ional Application No PCT/US 98/25551

		,			98/25551
Patent document cited in search repo		Publication date		atent family member(s)	Publication date
FR 2735145	Α	13-12-1996	AU	6229796 A	09-01-1997
			WO	9641888 A	27-12-1996
WO 9707199	Α	27-02-1997	US	5733749 A	31-03-1998
			AU	6715196 A	12-03-1997
			CA	2229488 A	27-02-1997
			EP	0845030 A	03-06-1998
WO 9821340	Α	22-05-1998	AU	5430798 A	03-06-1998
WO 9635795	Α	14-11-1996	US	5633362 A	27-05-1997
			AU	5722996 A	29-11-1996
			CA	2220441 A	14-11-1996
			EP	0827543 A	11-03-1998
			US	5821092 A	13-10-1998
WO 9635796	Α	14-11-1996	US	5686276 A	11-11-1997
			AU	5678996 A	29-11-1996
			CA	2220880 A	14-11-1996
			EP	0826057 A	04-03-1998
WO 9635799	Α	14-11-1996	US	5599689 A	04-02-1997
•			AU	5722896 A	29-11-1996
			CA	2220396 A	14-11-1996
			ΕP	0824595 A	25-02-1998
			JP	10507082 T	14-07-1998
WO 9821339	Α	22-05-1998	AU	5248498 A	03-06-1998
			AU	5507698 A	03-06-1998
			WO	9821341 A	22-05-1998
WO 9821341	Α	22-05-1998	AU	5248498 A	03-06-1998
			ΑU	5 507 698 A	03-06-1998
		•	WO	9821339 A	22-05-1998